[
  {
    "objectID": "index.html#clinical-pharmacologist-and-associate-professor-of-medicine--infectious-diseases",
    "href": "index.html#clinical-pharmacologist-and-associate-professor-of-medicine--infectious-diseases",
    "title": "Russell Lewis",
    "section": "CLINICAL PHARMACOLOGIST AND ASSOCIATE PROFESSOR OF MEDICINE- INFECTIOUS DISEASES",
    "text": "CLINICAL PHARMACOLOGIST AND ASSOCIATE PROFESSOR OF MEDICINE- INFECTIOUS DISEASES\nThis site serves as a repository for teaching materials, lecture slides, and links to current research projects. More information is available via my University of Padua Webpage or from my curriculum vitae.\n\nPlease follow the following link for my conflict of interest disclosure."
  },
  {
    "objectID": "index.html",
    "href": "index.html",
    "title": "Russell E. Lewis",
    "section": "",
    "text": "Clinical Pharmacologist and Associate Professor of Medicine-Infectious Diseases\nThis site serves as a repository for teaching materials, lecture slides, and links to current research projects.  More information is available via my University of Padua Webpage or from my curriculum vitae.\n\nPlease follow the following link for my current conflict of interest disclosures.\nProfessional photos can be downloaded here\nContact me: russelledward.lewis@unipd.it"
  },
  {
    "objectID": "about.html",
    "href": "about.html",
    "title": "Who is Russell Lewis?",
    "section": "",
    "text": "I am a clinical pharmacologist and Associate Professor of Medicine- Infectious Diseases (MED/17) in the Department of Molecular Medicine at the University of Padua. I was born and raised in the state of Kansas in the United States of America. I earned my Doctor of Pharmacy (Pharm.D.) degree from the University of Kansas, followed by post-graduate clinical residency training at Barnes-Jewish Hospital in St. Louis, Missouri. I then completed an infectious diseases research fellowship at the University of Iowa with a focus on antifungal pharmacology.\nI have over 25 years experience in the clinical care of immunocompromised patients and laboratory and clinical research of antimicrobial pharmacokinetics and pharmacodynamics. My current focus is on the development of prognostic risk models and decision support tools for the diagnosis and treatment of fungal infections and multidrug resistant bacteria. I also serve as a Senior Pharmacokinetics/Pharmacodynamics Editor for the Journal of Antimicrobial Chemotherapy.\nOutside of work hours, my free time is spent with my wife Marta, son Marco, dog Luli …and on long bike rides following the Veneto strade sterrate."
  },
  {
    "objectID": "cv.html",
    "href": "cv.html",
    "title": "Russell Edward Lewis",
    "section": "",
    "text": "I am an Associate Professor of Infectious Diseases in the Department of Molecular Medicine at the University of Padua and a clinical pharmacologist. I have over 25 years experience in laboratory and clinical research of antimicrobial and antifungal pharmacokinetic and pharmacodynamics in immunocompromised hosts. My current research focuses on the development and incorporation of prognostic risk models and decision/dosing support tools for fungal infections and multidrug resistant bacteria.\nlast updated: July 17, 2023"
  },
  {
    "objectID": "cv.html#contact-information",
    "href": "cv.html#contact-information",
    "title": "Russell Edward Lewis",
    "section": "Contact information",
    "text": "Contact information\n(Office): via Gabelli 63, 35121 Padova  russelledward.lewis@unipd.it \n(Home): Via Fortunato Venanzio, 60  Treviso, Italy 31100  +39 345 309 9843  russ.e.lewis@gmail.com  www.russlewisid.com"
  },
  {
    "objectID": "cv.html#birthdate",
    "href": "cv.html#birthdate",
    "title": "Russell Edward Lewis",
    "section": "Birthdate",
    "text": "Birthdate\n03-June-1972, Salina, Kansas, United States of America"
  },
  {
    "objectID": "cv.html#citizenship",
    "href": "cv.html#citizenship",
    "title": "Russell Edward Lewis",
    "section": "Citizenship",
    "text": "Citizenship\nUnited States of America; Permanent Residency Visa, Italy"
  },
  {
    "objectID": "cv.html#research-profiles",
    "href": "cv.html#research-profiles",
    "title": "Russell Edward Lewis",
    "section": "Research Profiles",
    "text": "Research Profiles\n\nORCID ID: 0000-0002-2002-4339\nGoogle scholar: Profile\nSCOPUS: 7404846664"
  },
  {
    "objectID": "cv.html#professional-experience",
    "href": "cv.html#professional-experience",
    "title": "Russell Edward Lewis",
    "section": "Professional Experience",
    "text": "Professional Experience\n2023- Associate Professor of Infectious Diseases (MED/17) | Dipartimento di Medicine Molecolare, Università degli studi di Padova  Padova, Italy\n2013-2023 Associate Professor of Infectious Diseases (MED/17) | Dipartimento di Scienze Mediche e Chirurgiche, Alma Mater Studiorum Università di Bologna  Bologna, Italy\n2011-2012 Full Professor with Tenure, Department of Clinical and Administrative Sciences, University of Houston College of Pharmacy  Houston, Texas\n2005-2011 Associate Professor with Tenure, Department of Clinical and Administrative Sciences, University of Houston College of Pharmacy  Houston, Texas\n2005-2007 Chair, ad interm,Department of Clinical and Administrative Sciences, University of Houston College of Pharmacy  Houston, Texas\n2000-2011 Adjunct Faculty, Division of Infectious Diseases, Infection Control and Employee Health, The University of Texas M.D. Anderson Cancer Center  Houston, Texas\n1999-2005 Assitant Professor, Department of Clinical and Administrative Sciences, University of Houston College of Pharmacy  Houston, Texas"
  },
  {
    "objectID": "cv.html#education",
    "href": "cv.html#education",
    "title": "Russell Edward Lewis",
    "section": "Education",
    "text": "Education\n1990-1996 Doctor of Clinical Pharmacy (Pharm.D.), University of Kansas  Lawrence, Kansas\n1996-1997 Clinical Pharmacy Residency, Barnes-Jewish Hospital, Washington Univeristy Medical Center  St. Louis, Missouri\n1997-1999 Infectious Diseases Research Fellowship, University of Iowa Colleges of Pharmacy and Medicine  Iowa City, Iowa"
  },
  {
    "objectID": "cv.html#training-courses",
    "href": "cv.html#training-courses",
    "title": "Russell Edward Lewis",
    "section": "Training courses",
    "text": "Training courses\n2005 Woods Hole Marine Biology Laboratories: Molecular Mycology: Current Approaches to Fungal Pathogenesis  Woods Hole, Massachusetts"
  },
  {
    "objectID": "cv.html#professional-licensure",
    "href": "cv.html#professional-licensure",
    "title": "Russell Edward Lewis",
    "section": "Professional Licensure",
    "text": "Professional Licensure\n1997- Licensed Pharmacist: Missouri (Inactive; Previously licensed in Texas)\n2001-2015 Board Certified Pharmacotherapy Specialist  Added qualifications in infectious diseases"
  },
  {
    "objectID": "cv.html#clinical-experience",
    "href": "cv.html#clinical-experience",
    "title": "Russell Edward Lewis",
    "section": "Clinical Experience",
    "text": "Clinical Experience\n2024-Present Hematopoetic Stem Cell Transplant and Cellular Therapy, UOC Ematologia, Dipartimento di Medicina Interna, Ospedale Ca’ Foncello, ULSS2 - Marca Trevigiana  Treviso, Italy\n2012-2023 UO Malattie Infettive, IRCCS Policlinico S. Orsola-Malpighi, University of Bologna  Bologna, Italy\n2000-2011 Clinical Staff (Pharmacy) and Faculty (Medicine) Infectious Diseases Consultation Services, The University of Texas M.D. Anderson Cancer Center  Houston, Texas\n1997-1999 Clinical Adjunct Faculty Infectious Diseases/Internal Medicine, University of Iowa College of Pharmacy  Iowa City, Iowa\n1996-1997 Clinical Pharmacist, Barnes-Jewish Hospital  St. Louis, Missouri\n1995-1996 Pharmacy Intern, St. Francis Regional Hospital  Topeka, Kansas\n1992-1995 Laboratory Research Assistant, Department of Pharmacology and Toxicology, University of Kansas School of Pharmacy  Lawrence, Kansas"
  },
  {
    "objectID": "cv.html#post-doctoral-students",
    "href": "cv.html#post-doctoral-students",
    "title": "Russell Edward Lewis",
    "section": "Post-doctoral students",
    "text": "Post-doctoral students\n2002-2004 Nathan Widerhold, Pharm.D.  Thesis: Pharmacodynamics of caspofungin in a murine model of invasive aspergillosis  Houston, Texas\n2018-2021 Irene Zaghi, M.D.  Infectious Diseases Specialization Thesis: Bayesian Diagnostic Meta-Analysis of Blood Time To positivity for Predict Infection Outcome and Catheter-Related Bloodstream Infections  Bologna, Italy"
  },
  {
    "objectID": "cv.html#doctoral-students",
    "href": "cv.html#doctoral-students",
    "title": "Russell Edward Lewis",
    "section": "Doctoral students",
    "text": "Doctoral students\n2014-2015 Irene Zaghi, M.D.  Thesis: Diagnostic Meta-Analysis of Serum Bactericidal Testing  Bologna, Italy\n2018-2019 Giulia De Luca, M.D  Thesis: Use of State Transition Models to Explore the Utility of Selective Digestive Tract Decontamination in Patients Colonized with Carbapenem-Resistant Enterobacteriaceae  Bologna, Italy\n2019-2020 Mayleko Mohamedwais, M.D.  Thesis: Development and internal validation of a model to predict early invasive mold disease risk in patients undergoing allogeneic hematopoietic stem cell transplantation  Bologna, Italy\n2021-2022 Nicola Montovani, M.D.  Thesis: Incorporation of genetic risk factors in a clinical risk prediction score for invasive mold disease for patients undergoing treatment for hematological malignancies  Bologna, Italy"
  },
  {
    "objectID": "cv.html#teaching-experience",
    "href": "cv.html#teaching-experience",
    "title": "Russell Edward Lewis",
    "section": "Teaching Experience",
    "text": "Teaching Experience\n2023-Present  University of Padua, Padua, Italy\n University of Padua, Padua, Italy\n2023-Present  University of Padua, Padua, Italy  MEP 2491 Infectious Diseases - Principles of antibiotic therapy - Antibiotic resistance in ESKAPE pathogens - Antibiotic allergies - Fever of unknown origin - Invasive fungal infections - Infectious diarrhea - Intraabdominal infections - Parasites-malaria and leishmaniasis\n2021-2023 9730- Global Health, Antimicrobial Therapy and Vaccines  University of Bologna, Bologna, Italy  Course website: www.uniboglobalhealth.com\n2014-2021 79947 – Malattive Infettive II  University of Bologna, Bologna,Italy - Antimicrobial pharmacokinetics and pharmacodynamics - Antifungal pharmacokinetics and pharmacodynamics\n2014-2021 PHAR 5208 Infectious Diseases Therapeutics, Course coordinator  University of Houston College of Pharmacy, Houston, Texas - The clinician and the microbiology laboratory - Aerosolized and percutaneous antibiotic dosing - Immunology of ID - Antibiotic hypersensitivity and allergy - Vaccination - Antifungal therapy\n2007-2011 PHAR 4308. Cellular Life Sciences II  University of Houston College of Pharmacy, Houston, Texas - Adversarial pathogen strategies during infection, Parts 1-3 - Immunobiologicals used in transplant and oncology\n2007-2011 PCOL 6371-Advanced Pharmacology II  University of Houston College of Pharmacy, Houston, Texas - Principles of Host Immunity - Immunopharmacology - Pharmacology of anti-inflammatory agents\n2000-2010 PHCA 5209 Infectious Diseases Pharmacotherapeutics II  University of Houston College of Pharmacy, Houston, Texas - Essentials of in vitro testing of antimicrobials - Molecular mechanisms of antibacterial resistance - Quinolone antibiotics - Macrolides, lincosamides, streptogramins, and linezolid - Systemic antifungal agents - Immunology of Infectious Diseases - Vaccinations\n2007-2010 University of Houston Residency Certificate Program  University of Houston College of Pharmacy, Houston, Texas - Academic careers - Scientific publication\n1999-2011 PHAR 5581. Advanced Pharmacotherapeutics, Co-course coordinator  University of Houston College of Pharmacy, Houston, Texas - Systemic Fungal Infections - Infective Endocarditis - Sexually Transmitted Diseases - Septic Meningitis - Tuberculosis - Immunology of auto-immune diseases - Drug Hypersensitivity\n2001-2011 PHAR 5229 Research Methodologies in Pharmaceutical Research  University of Houston College of Pharmacy, Houston, Texas  - Animal Models in Pharmaceutical Development\n2001-2011 PHAR 5682 Infectious Diseases Clinical Clerkship  University of Houston College of Pharmacy and The University of Texas M.D. Anderson Cancer Center, Houston, Texas - Hematological Malignancies /Hematopoetic Stem Cell Transplant Consult Service - Solid Tumor Malignancies Consult Service - Intensive Care Unit Consult Service\n2002-2003 PHAR 5372 –Pharmacy Law and Ethics, Course Coordinator  University of Houston College of Pharmacy, Houston, Texas \n2001-2005 PHPR 646 – Pharmacotherapy I. Invited lecturer  University of Kansas School of Pharmacy,  Kansas Medical Center, Kansas City, Kansas - Invasive fungal infection - Sepsis\n2001-2011 Infectious Diseases Fellows Core Curriculum  The University of Texas M.D. Anderson Cancer Center and Baylor College of Medicine, Houston, Texas - Antibiotic and Tumor-Related Fever - New Treatment Modalities for Acute and Chronic Leukemia - Infectious Complications in Chronic Lymphocytic Leukemia - The Pharmacology of Sepsis - Iatrogenic Immunosuppression - Overview of Antifungal Pharmacology - Overview of Immunosuppression Associated with Cancer Chemotherapy - Antibiotic Hypersensitivity\n2000-2001 Diabetes TX-Pharm Elective  University of Houston College of Pharmacy, Houston, Texas - Infections in the Diabetic Patient\n2000-2011 PHAR 5365 Pharm.D Seminar  University of Houston College of Pharmacy, Houston, Texas\n1998-1999 Pharmacotherapy IV  University of Iowa College of Pharmacy, Iowa City, Iowa - Febrile neutropenia - Infective endocarditis\n1997-1999 Pharmacotherapy IV, Group case discussion leader  University of Iowa College of Pharmacy, Iowa City, Iowa\n1997-1999 Introduction to Pharmaceutical Care, Group leader  University of Iowa College of Pharmacy, Iowa City, Iowa\n1997-1999 Instructor, Infectious Diseases Research Elective  University of Iowa College of Pharmacy, Iowa City, Iowa\n1997-1999 Instructor and context evaluator, Honors Seminar  University of Iowa College of Pharmacy, Iowa City, Iowa\n1996-1997 Adjunct Clinical Instructor at Barnes-Jewish Hospital  St. Louis College of Pharmacy, St. Louis, Missouri - Infectious Diseases Clerkship - Internal Medicine Clerkship - Critical Care Clerkship - Ambulatory Care Clerkship (VA Medical Center)\n1996-1997 Infectious Diseases Pharmacotherapy  St. Louis College of Pharmacy, St. Louis, Missouri - Overview of Microbiological Testing - Overview of Antibacterial Resistance"
  },
  {
    "objectID": "cv.html#invited-lectures",
    "href": "cv.html#invited-lectures",
    "title": "Russell Edward Lewis",
    "section": "Invited Lectures",
    "text": "Invited Lectures\n2022 Importance of pharmacokinetics/pharmacodynamics in the immunocompromised host  21st Immunocompromised Host Society Symposium on Infections in the Immunocompromised Host, Basel, Switzerland\nAntifungal prophylaxis in the tageted chemotherapy era  University of Manitoba, Hematology-Infectious Diseases Conference (Virtual),  Winnipeg, Manitoba, Canada  University of Alberta, Hematology Grand Rounds (Virtual)  Edmonton, Alberta, Canada\nOverview of the antifungal pipeline in 2022  F2G Medical Laison Training (Virtual)\n2021\nAntimicrobial PK in critically-ill: CRRT, ECMO and Drug interactions  European Hematology (Virtual). Association Annual Meeting. June 11, 2021.\nAntifungal pipeline for invasive candidiasis  Bertino bloodstream infection meeting (Virtual hybrid), Bertino (Romagna), Italy\nAntifungal stewardship best practices  SHAPE 2021 Meeting (Virtual)\nAntifungal PK/PD in the critically ill and hematology patient  Antifungal therapy: Myths and truths (Virtual hybrid), Brazil\nAntifungal TDM in critically-ill patients, which drugs and how?  ATHENA 2021 Conferernce (Virtual hybrid), Athens, Greece\nWhat is the right dose for CRRT and ECMO?  ATHENA 2021 Conferernce (Virtual hybrid), Athens, Greece\nSpiraling empiricism vs. science: The delimma of breakthrough fungal infections  Society of Infectious Diseases Pharmacists 2021 Fall Business Meeting (Virtual)\nAntifungal therapy in the era of targeted chemtoherapy for hematological maliganancies  Canadian Infectious Diseases Meeting (Virtual)\nAntifungal therapy considerations in the tageted chemotherapy era  Canadian Hematology National Conference (Virtual)\n2020 COVID-19 and invasive aspergillosis: Lessons learned.  Gilead Care Webinar Series (Virtual).\nThe growing impact of targeted chemotherapy on the treatment of invasive fungal diseases  Ambisome 30 year Anniversary Symposium. (Virtual).\nOptimizing antifungal dosing for bloodstream and intraabdominal candidiasis  Gilead CARE Meeting, Brazil (Virtual)\nDifficult cases in managing antifungal drug interactions with targeted chemotherapies  Gilead CARE Meeting, Brazil (Virtual)\nManaging drug interactions in the era of targeted therapies for hematological malignancies  Kings College London Hematology Grand Rounds (Virtual)\n2019 How I manage drug interactions in the era of targeted therapies for hematological malignancies 12th Annual Gilead Care Meeting, Paris, France\nPharmacological basis for treatment of mucormycosis 2nd Henry Schuler Symposium on Mucormycosis, Chicago, IL USA\nTriazole Interactions with FLT3 inhibitors  9th Trends in Medical Mycology Nice, France\nEchinocandin dosing, can we do better?  9th Trends in Medical Mycology Nice, France\nHow will targeted therapies in hematological disease change the management of fungal infections?  55th Annual British Society Medical Mycology Meeting, Sheffield, United Kingdom\n2018 How to manage antimicrobial pharmacokinetic variability in the critically-ill patient  The European Society of Intensive Care Medicine (ESICM) Infections in ICU: Modern Management Fellowship Program: Modena, Italy\nPK/PD issues in septic shock  Antimicrobial Therapy in Immunocompromised and Critically Ill Patients: Management and Perspectives (ATCIP), Lugano, Switzerland\nDebate-Are polyenes still relevant in 2018?  20° Immunocompromised Host Society Meeting, Athens, Greece\nOptimizing antimicrobial pharmacokinetics in the ICU patient  20° Immunocompromised Host Society Meeting, Athens, Greece\nPro-Con Debate “Con: Antifungal MICs are not as useful as you think with Cornelia Lass-Florl  27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Madrid, Spain\nPrinciples of antifungal therapy, Principles of antibiotic therapy  Hematology resident Seminar. L’Istituto di Ematologia “Seràgnoli” Bologna. Italy\nThe role of CT pulmonary angiography for the diagnosis of invasive mold disease  54th Annual British Society Medical Mycology Meeting, Bristol, United Kingdom\nCan we improve the management of invasive mold disease using CT pulmonary angiography?  Infectious Diseases Grand Rounds, Centre hospitalier universitaire Vaudois (CHUV),Lausanne, Switzerland\nThe Antifungal Pipeline  La micologia del III millennio – 2° edizione. Pescara, Italy\n2017 How to manage antimicrobial pharmacokinetic variability in the critically-ill patient  The European Society of Intensive Care Medicine (ESICM) Infections in ICU: Modern Management Fellowship Program. Modena, Italy\nImmunopharmacology of antifungal therapy  Gilead Immunology Forum, Frankfurt, Germany\nClinical considerations for the selection of antifungal therapy  Breaking the Mould Meeting. London, UK\nRadiological diagnostics in neutropenic and non-neutropenic patients  Joint annual Meeting of the Swiss Societies for Microbiology, Infectious Diseases, Hospital Hygiene, Tropical Medicine and Parasitology, and Tropical and Travel Medicine (SSI, SSHH, SSTMP, SSTTM). Basel, Switzerland.\nAntifungals and kidney Injury  9° Congresso Nazionale DiTMO 2017. Geneva, Italy\nNew Therapeutics for mucormycosis  27th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Vienna, Austria\nDifferentiating fungal versus non-fungal pathology by CT imaging  Fungal Infection Update Meeting. London, UK\n2016 Antifungal pharmacology in the CNS  Gilead CARE Meeting, Munich, Germany\nAntifungal therapy update  S.Orsola-Malpighi Open Days Symposium, Bologna, Italy\nFarmacocinetica degli immunosopressor  Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) Cagliari, Italy\nFarmacocinetica degli antifungin  Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO) Cagliari, Italy\nPharmacokinetics and pharmacodyanamics of antifungals  New Perspectives in the Treatment of Invasive Fungal Infections Meeting, Bologna, Italy\nHow to optimize liposomal amphotericin B dosing  Breaking the Mould Meeting, London, United Kingdom\nControversies in antifungal therapy  Gruppo Italiano per il Trapianto di Midollo Osseo (GITMO), Bologna, Italy\nTargeting fungal infections in the CNS-A summary of in vitro and in vivo experience  INFORM Meeting, Dubai, UAE\nUpdate on antifungal therapeutics  Mycology Update 2016, Parma, Italy\nBeyond direct antifungal activity-The immunomodulatory effect of echinocandin antifungals  26th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID), Amsterdam, Netherlands\nAntifungal therapeutic drug monitoring-Pro/Con debate: “PRO: When we should recommend TDM.  European Bone Marrow Transplantation (EBMT) Annual Meeting, Valencia, Spain\nSignificant papers in infectious diseases  Update on the American Society of Hematology Meeting (Post-ASH). Genova, Italy\nAntifungal stewardship performance indicators and assessment  Transdisciplinary ECMM Antifungal Stewardship Workshop, Wesel, Germany\n2015 Antifungal stewardship in hematology units  Italy & Spain Friendship and opinions about antimicrobial stewardship programs. Bologna, Italy\nReevaluating the role of liposomal amphotericin B in the treatment of life-threatening fungal diseases  Breaking the Mould Symposium” London, United Kingdom\nOptimizing antifungal dosing  Ankara Infectious Diseases Symposium, Ankara, Turkey\nOptimizing Antifungal Dosing  Turkish Society of Haematology, Istanbul, Turkey\nDo we routinely underdose antifungal therapy?  Izmir Infectious Diseases Symposium, Izmir, Turkey\nAntimicrobial Susceptibility Testing-A view from the pharmacologist  XI Corso Avanzato Di Terapia Antibiotica Pisa, Italy\n2014 Safety and toxicity of antifungal therapy  Infezioni fungine nel trapianto di organo solido: un anno dopo. Bologna, Italy\nRisk Models for Invasive Fungal Disease  54th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, USA\nOptimizing antimicrobial therapy in the critically-ill-  Sepsi: Certezze Controversie nella diagnosi e nella gestion, Forli, Italy\nAntimicrobial pharmacokinetics and dynamics in the critically-ill  Stage Formativo. Società Italiana di Malattie Infettive e Tropicali (SIMIT). Bologna, Italy\nAntifungal penetration into difficult sites  18th Biennial Symposium of the Immunocompromised Host Society (ICHS), Berlin, Germany\nManagement of MDR organisms  18th Biennial Symposium of the Immunocompromised Host Society (ICHS), Berlin, Germany\nRisk-Assessment for invasive mold diseases  18th Biennial Symposium of the Immunocompromised Host Society (ICHS), Berlin, Germany\nKey strategies for managing breakthrough fungal infections  Paul Ehrlich Society for Chemotherapy-Spring Mycoses Meetings, Bonn, Germany\nFilling the gaps-New tools to identify invasive mold disease in hematology patients  Visiting Professor Grand Rounds, Infectious Diseases, University of Cologne, Cologne Germany\nDrug interactions and tolerability of triazoles  6th Advances Against Aspergillus Conference, Madrid, Spain\n2013 Antimicrobial susceptibility testing-A view from the pharmacologist  X Corso Avanzato Di Terapia Antibiotica, Pisa, Italy\nPK:PD For the clinician-A 4 part lecture series  Invited Professor, Infectious Diseases Unit, University of Modena Modena, Italy\nInterazioni farmacologiche fra antifungini e farmaci antirigett  Infezioni fungine nel trapianto di organo solido: esperienze a confronto, Bologna, Italy\nPK:PD driven choice of antimicrobials in abdominal sepsis  Il Rischio infettivo in chirurgia addominale, Bologna, Italy\nCombination antifungal therapy-bench to bedside  7th International Transplant Infectious Diseases Conference, Vienna, Austria\nClinical Case- Voriconazole associated photoxicity  7th International Transplant Infectious Diseases Conference, Vienna, Austria\nAntimicrobial pharmacokinetics and dynamics in the Critically-Ill  Stage Formativo. Società Italiana di Malattie Infettive e Tropicali (SIMIT). Bologna, Italy\nRisk model for invasive mold disease in hematology patient  Fungal Diseases in Hematology: Translating Basic Science into Clinical Practice. Parma, Italy\nFungal meningitis outbreak in the United States  7° Congresso Nazionale DiTMO - Diagnostica E Terapia Delle Micosi Oppotuniche Genoa, Italy\nAntimicrobial pharmacokinetics and dynamics in the critically-ill  Stage Formativo. Società Italiana di Malettie Infettive e Tropicali (SIMIT). Bologna, Italy\nOverview of animal models of mucormycosis  ISHAM Zygomyctes workshop April, 2013, Utrecht, Netherlands\n2012 Optimizing antifungal therapy through pharmacokinetic/pharmacodynamics principles  Infectious Diseases Society of Portugal, Lisbon, Portugal\nUsing pharmacodynamics to set antifungal susceptibility breakpoints  52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, USA\nTreatment of MDR P. aeruginosa and A. baumanii infections.  17th International Symposium on Infections in Immunocompromised Hosts. Genoa, Italy\nDose escalation strategies of liposomal amphotericin B in the treatment of experimental Aspergillus terreus pneumonia.  18th Congress on the International Society for Human and Animal Mycology, Berlin, Germany\nAntimicrobial pharmacokinetics and dynamics in the critically-ill  Stage Formativo. Società Italiana di Malettie Infettive e Tropicali (SIMIT). Bologna, Italy\n2011 Is Antifungal susceptibility testing necessary in the Mmnagement of invasive candidiasis?  Pro-Con Debate. 49th Infectious Diseases Society of America Annual Meeting, Boston, Massachusetts, USA\nOverview of antifungal pharmacology  Sabati Ematologici della Romagna, Meldola, Italy\nOverview of the immunopharmacological mechanisms of antifungals  Aggionarmenti in Terapia Antifungina: La Parola Agli Esperti, Bologna, Italy\n2010 Optimized antifungal prophylaxis in the high-risk patient  45th Annual Midyear Meeting of the American Society for Health System Pharmacy, Anaheim, California\nManaging drug interactions with immunosuppressant agents Infectious Diseases Society of America (IDSA) 48th Annual Meeting, Vancouver, Canada\nChallenging cases in antifungal therapeutic drug monitoring Infectious Diseases Society of America (IDSA) 48th Annual Meeting, Vancouver, Canada\nThe interplay of innate immunity and antifungal resistance  Astellas Pharmaceutical Global Advisory, Vancouver, Canada\nTriazole antifungal pharmacokinetics and pharmacodynamics  CE program, Boston, Massachusetts\nUpdate on the management of invasive fungal infections  University of Illinois-Chicago Infectious Diseases CME Symposium, Chicago, Illinois\nThe ins and outs of scientific publication  Harris County Hospital Resident and Faculty Development Series, Houston, Texas\nAspergillus, steroids and antifungals- What every patient should know  3rd Advances Against Aspergillus Meeting, Rome, Italy\nAntibiotic Resistance Concerns in the Gyn-Onc Patient-  Gynecology-Oncology Grand Rounds. The University of Texas M.D. Anderson Cancer Center, Houston, Texas\nHow does antifungal pharmacology differ for mucormycosis vs. aspergillosis?  Henry Schuler Memorial Symposium. Chicago, Illinois\nManaging antifungal nephrotoxicity and hepatotoxicity  47th Meeting of the Infectious Diseases Society of America, Philadelphia, Pennsylvania\nManaging cytomegalovirus infections in transplant patients  Hematology Oncology Pharmacist Association (HOPA) CME webinar (Virtual)\nGetting with the Guidelines- Management of Invasive Candidiasis  CME Lecture Series provided in Philadelphia, Pennsylvania; Denver Colorado, San Jose, California and Los Angeles, California.\nControversies and questions surrounding the antifungal formulary  Teleconference CME series. Broadlane Pharmacy Management Group, Houston, Texas\n2009 Where are the new antibiotics?  University of Houston College of Pharmacy Infectious Diseases Pharmacy CE Symposium, Houston, Texas\nPharmacokinetic-pharmacodynamic optimization of antimicrobial dosing in the neutropenic patient  17th Annual King Hussein Cancer Center Conference, Amman, Jordan\nNew antimicrobials for neutropenic fever  17th Annual King Hussein Cancer Center Conference, Amman, Jordan\nControversies in the management of invasive candidiasis  Society of Hospital Medicine 2009 Annual Meeting, Chicago, Illinois\nKey pharmacological concerns in the management of invasive fungal infections  Visiting Professor- Case Discussions of Difficult Cases of Invasive Fungal Infections  Peking Medical University and College of Pharmacy, Beijing, China\nIntrapulmonary drug delivery and interactions with host cells  4th Trends In Medical Mycology (TIMM) Annual Meeting, Athens, Greece\nNew antimicrobials and antibiotic dosing strategies in neutropenic fever-  Hematologic Malignancies Conference 2009. Brussels, Belgium\nControversies in the management of invasive candidiasis  5th Annual Infectious Diseases- Critical Care Pharmacy CE Conference, Toronto, Ontario, Canada\n2008 Improving the pharmacology of invasive mould infections  Infectious Diseases Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, New York\nEvidence versus pragmatism in managing invasive candidiasis  Infectious Diseases Grand Rounds, University of Nebraska Medical Center, Omaha, Nebraska\nCases in antifungal therapeutic drug monitoring  Houston Infectious Diseases Pharmacy Network. Houston, Texas\n2007 The case for fluconazole as front-line therapy in invasive candidiasis: Pro-con debate  American Society of Heath-System Pharmacy Annual Meeting, Las Vegas, Nevada\nSystemic antifungal therapy-What every clinician should know  American Society of Heath-System Pharmacy Annual Meeting, Las Vegas, Nevada\nInterpreting antifungal susceptibility testing 47th Interescience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois\nSalvage antifungal therapy, Combination therapy, and Antifungal pharmacodynamics  AB Biodisk ABLE Course, Stockholm Sweden\nAntifungal therapeutic drug monitoring-  Pharmacy Grand Rounds, Memorial Sloan-Kettering Cancer Center, New York, New York\nWhat are the real differences between the echinocandins?  Department of Hematology and Transplantation. Oregon Health Sciences Center, Portland, Oregon\nManaging infections in the immunocompromised host  Hematology Oncology Pharmacist Association (HOPA) Annual Meeting. Denver, Colorado\n2006 The new antifungal formulary  City of Hope Pharmacotherapy Symposium. Anaheim, California\nAntifungal pharmacodynamics- A focus on the echinocandins-  17th European Conference on Chemotherapy, Microbiology and Infectious Diseases. Munich, Germany\nAntifungal therapeutic drug monitoring  Blood and Marrow Transplantation Case Conference. M.D. Anderson Cancer Center, Houston, Texas\nMaking sense of the antifungal formulary  Malaysian Society of Hematology Conference, Kuala Lumpur, Malaysia\nRole of new antifungal agents in the management of invasive fungal infections  Hematology Grand Rounds. Hong Kong Sanatorium Hospital. Hong Kong, China\nNew drugs and new opportunities for combination antifungal therapy  Grand Rounds. Queen Mary Hospital. Hong Kong, China\nRole of new antifungal agents in the management of invasive fungal infections  City Hematology Conference. Beijing China\nRole of new antifungal agents in the management of invasive fungal infections  Infectious Diseases Citywide Conference, Shanghai, China\nAntifungal therapy-Consensus and controversy  UCSF Medical Center Pharmacy Forum. San Francisco, California\nInvasive fungal infection-consensus and controversies  UCLA Infectious Diseases Grand Rounds, Los Angeles, California\nManagement of invasive fungal infections-the MDACC approach ABLE Susceptibility Course, Stockholm, Sweden\nAntifungal formulary 2006  Tennessee ACCP Summer Chapter Meeting. Memphis, Tennessee\nAntifungal formulary 2006  St. Jude’s Children’s Hospital, Memphis, Tennessee\nAntifungal controversies 2006-  Vanderbilt Department of Infectious Diseases, Nashville, Tennessee\nConundrums of testing antifungal combinations in the laboratory  International Society of Human and Animal Mycology Congress, Paris, France\nDifficulties in establishing in vitro/in vivo correlations with antifungal activity  International Society of Human and Animal Mycology Congress, Paris, France\nAntifungal formulary 2006  Oregon Health Sciences Center. Department of Infectious Diseases, Portland, Oregon\nAntifungal formulary-Best picks-  University of Houston College of Pharmacy Infectious Diseases CE Symposium, Houston, Texas\nDo we routinely underdose antifungal therapy?  British Society for Medical Mycology Annual Meeting, Clontarf Castle, Dublin, Ireland\nManaging drug interactions in the patient with aspergillosis  2nd Annual Advances Against Aspergillosis Meeting, Athens Greece\nOverview of antifungal pharmacology  Frontline CE Symposium. Houston, Texas\n2005 Drosophila as a high-throughput model for studying fungal pathogenesis-  Texas-UK Biosciences Research Collaborative, London School of Tropical Health and Hygiene, London, United Kingdom\nAntifungal Susceptibility to guide empiric therapy and combination therapy  AB Biodisk Antifungal Susceptibility Course, Stockholm, Sweden\nQuinolone-associated MRSA-Significant papers in infectious diseases  American College of Clinical Pharmacy Annual Meeting, San Francisco, California\nDecisions concerning the use of combination antifungal therapy  American College of Clinical Pharmacy Annual Meeting, San Francisco, California\nNeutrophil subsets and infection-New insights into “adaptable” innate immunity  MD. Anderson Infectious Diseases Grand Rounds\nManagement of infection in the immunocompromised host  Merck Acute Care Sales Force National Training Symposium Jacksonville, Florida\nCombination antifungal therapy-Pro vs. Con-  North Carolina Chapter of the American College of Clinical Pharmacy, Durham, North Carolina\nNew antifungals, New treatment options  Louisiana State University Charity Hospital Infectious Diseases Grand Rounds\nNew frontiers in the treatment of invasive fungal infections-  Making a Difference Pharmacy CE Conference, Carefree, Arizona\nNew frontiers in the treatment of invasive fungal infections- Alabama Society of Health-System Pharmacists Annual Meeting, San Destin, Florida\nNew frontiers in the treatment of invasive fungal infections- New Orleans Society of Health System Pharmacists, New Orleans, Louisiana\nDo we routinely under-dose antifungal therapy?  National Institute of Allergy and Infectious Diseases Grand Rounds, National Institutes of Health, Bethesda, Maryland\nToxigenic moulds in Texas: New insights into the pathogenesis of an opportunistic pathogen  The University of Tennessee College of Pharmacy, Memphis, TN\n2004 Practical management of multidrug resistant infections  Session moderator. ASHP Annual Meeting, Orlando, Florida\nEvidence surrounding consensus recommendations for monitoring of serum vancomycin levels  ASHP Annual Meeting, Orlando, Florida\nCase studies in the selection of antifungal therapy  Division of Infectious Diseases, Henry Ford Hospital, Detroit, Michigan\nImmunology of effective antifungal therapy  Wayne State College of Pharmacy, Detroit, Michigan\nOverview of antifungal pharmacology, antifungal resistance, Combination antifungal therapy  AB Biodisk Antifungal Susceptibility Course, Stockholm, Sweden\nPharmacotherapy of invasive fungal infections University of Connecticut School of Pharmacy ID Symposium, Storrs, Conneticut\nTreatment of fungal infection in the ICU patient  New England Critical Care Pharmacy Symposium. Newton, Massachusetts\nNewer antifungal therapies and their role in the therapy of invasive mycoses Pharmacy Society of Wisconsin Annual Meeting. Madison, Wisconsin\nNew antibiotics for the perfect storm of infectious diseases  Texas Society of Health Systems Annual Meeting. Houston, Texas\n2003 Antifungal therapy and Evedence-based medicine  ASHP Annual Meeting, New Orleans, Louisiana\nThe perfect storm in infectious diseases  ASHP Section of Clinical Specialists and Scientist Network Assembly. Moderator. ASHP Annual Meeting, New Orleans, Louisiana\nAntibiotic selection in gynecology-oncology patient  Gynecology-Oncology Grand Rounds. The University of Texas M.D. Anderson Cancer Center, Houston, TX\nSignificant papers in pharmacotherapy—SARS  American College of Clinical Pharmacy Annual Meeting, Atlanta, Georgia\nMenacing moulds and new antifungals  Gulf Coast Society of Health-System Pharmacists, Houston, Texas\nAntifungal therapy consideration in the transplant patient  Good Samaritan Hospital, Phoenix, Arizona\nAntifungal resistance-Is the fluconazole era over?  University of Missouri-Kansas City Infectious Diseases Symposium\nAntifungal resistance  Oklahoma Society of Health System Pharmacist Annual Meeting, Oklahoma City, Oklahoma\nPharmacotherapy of invasive candidiasis  Citywide Pharmacy CE Conference. Denver, Colorado\nInvasive candidiasis  St. Lukes Hospital, Houston, Texas\nMenacing moulds  Great Lakes CE Conference. Grand Rapids, Michigan\nEchinocandins and Lipid AMB formulations  Mycoses 2002 Symposia (given with Drs. Gerald Bodey, Dimitrios Kontoyiannis, and Issam Raad), Houston, Texas\n2002 Beyond Microdilution Broth Antifungal Susceptibility Testing  Pre-symposium to the 41st, 42nd and 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Antifungal Susceptibility Testing for the Clinician. San Diego, California, Chicago, Illinois, and Washington, D.C\nRespiratory Infection Update  Texas Academy of Family Practice Physicians- Fall CME Symposium, Houston, Texas\nManagement of Invasive Fungal Infections in the Critically Ill Patient  Infectious Disease Pharmacotherapy CE Symposium, San Antonio, Texas\nNew Agents and Evolving Strategies for Life-Threatening Fungal Infections in the Immunocompromised Patients  The 24th Annual M.D. Anderson Cancer Center Pharmacy Symposium on Cancer Chemotherapy. Houston, Texas\nControversies in Antifungal Pharmacology  Citywide ID conference. Seattle, Washington\nIs Immunodysregulation a Virulence Factor for Aspergillus?  Houston Area Mycoses Study Group. The University of Texas M.D. Anderson Cancer Center, Houston, Texas\nThe Immunology of Effective Antifungal Therapy  M.D. Anderson Cancer Center Infectious Diseases Research Conference, Houston Texas\n2001 New antifungal formulations, new antifungal targets  Grand Rounds, Fairfax Hospital, Fairfax, Virginia  Baylor Medical Center, Dallas, Texas  Texas Society of Health System Pharmacists, Annual Meeting Austin, Texas  Kentucky Society of Health System Pharmacists, Annual Meeting Louisville, Kentucky  Infectious Diseases Pharmacy Symposium, Albuquerque, New Mexico  Infectious Diseases Citywide Symposium, Phoenix, Arizona  Oklahoma Society of Health System Pharmacists, Tulsa Oklahoma\nThe Dilemma of Defining Optimal Treatment Strategies for Refractory Mycoses  2001 American College of Clinical Pharmacy Meeting, Tampa, Florida\nNew antibiotic update-  Ft. Bend Physician Medical Society, Sugarland, Texas\nPharmacology of Current and Future Antifungals  Infectious Diseases Morning Rounds, Barnes-Jewish Hospital at Washington University Medical Center, St. Louis, Missouri\nPharmacology of Current and Future Antifungals  Mycoses 2001 (with Drs. John Rex, Richard Hamill, and Dimitrios Kontoyiannis), Houston, Texas\n2000 New Antimicrobials for Resistant Gram-Positive Infections  Parkland Medical Center Infectious Diseases Dallas, Texas\nWhat is Considered Broad-Spectrum Therapy? A re-examination of the ATS Guidelines for nosocomial pneumonia  Memorial Southwest Hospital (Baylor) Grand Rounds, Houston, Texas\nControversies in the Management of Invasive Fungal Infections  Southwestern Med. School Infectious Diseases Grand Rounds, Dallas, Texas  Grand Rounds, Wilford Hall Medical Center, San Antonio, Texas  Clinical Updates 2000- Annual Meeting of the California Society of Health System Pharmacists, Palm Springs, California  Winter CE meeting of the Southern Colorado Society of Health System Pharmacists, Colorado Springs, Colorado  Grand Rounds, Memorial Southeast Medical Center, Houston, Texas\nNew Antimicrobials for the Post-Antibiotic Era  UH Infectious Diseases Continuing Education Symposium, Texas Medical Center Marriott Hotel, Houston, Texas\nAre We Nearing the End of the Fluconazole Era?  Advances in Oncology Institutional Grand Rounds. M.D. Anderson Cancer Center (Given with Drs. Gerald Bodey and Issam Raad). Houston, Texas\nAntifungal Pharmacodynamics  M.D. Anderson Infectious Diseases Research Conference, Houston Texas\nDifferentiating the Quinolones-Do we really need new agents?  Resident Grand Rounds, Corpus Christi, Texas  Houston Area Society of Otolaryngologists, Houston, Texas.\nImplications of streptococcal resistance for antibiotic therapy  Border Issues and Resistance, University of Texas CME Otolaryngology Conference. McAllen, Texas\n1999 Antifungal Pharmacodynamics-What Emerging Data Are Telling Us About Dosing Antifungal Therapy  Visiting Professor Series; Department of Pharmacological and Pharmaceutical Sciences. University of Houston College of Pharmacy. Houston, Texas\nShould Combinations of Amphotericin B and Fluconazole Be Used for the Treatment of Candidemia?  University of Wisconsin College of Pharmacy, Madison, Wisconsin\n1998 IDSA Guidelines for the Treatment of Community Acquired Pneumonia:Resistant S. pneumoniae and the Role of Quinolones  Fellowship Forum. University of Iowa, Iowa City, Iowa\n1997 Pharmacodynamic Evaluation of Combination Amphotericin B-Fluconazole Activity Using an In Vitro Infection Model  Fellow Seminar Series. University of Iowa. Iowa City, Iowa\nEvolving Role of Oral Antimicrobial Therapy-  Pulmonology Conference Series. Barnes-Jewish Hospital. Washington University Medical School. St. Louis, Missouri\nEvaluation of Colony Stimulating Factor Use in a Large Teaching Hospital  Midwest Residency Conference, Memphis, Tennessee\n1996 Colony Stimulating Factors as Adjunctive Treatment in Acute Myelogenous Leukemia  Residency Seminar Series. St. Louis, Missouri\nRational Use of Step-Down Oral Antibiotic Therapy-  Pharmacists Continuing Education. Barnes- Jewish Hospital, St. Louis, Missouri\n1995 Continuous infusion loop diuretics to overcome diuretic resistance Doctor of Pharmacy Seminar. University of Kansas Medical Center, Kansas City, Kansas"
  },
  {
    "objectID": "cv.html#publications",
    "href": "cv.html#publications",
    "title": "Russell Edward Lewis",
    "section": "Publications",
    "text": "Publications\nScopus author ID: 7404846664  314 peer-reviewed publications, H index 77, 18,686 citations \n\nLewis RE, Stanzani M, Morana G, Sassi C. Radiology-based diagnosis of fungal pulmonary infections in high-risk hematology patients: are we making progress? Current Opinion Infectious Diseases. 2023:36:250-256.\nBartoletti, M Antonelli, A Bussini, L Corcione, S Giacobbe, DR Marconi, L Pascale, R Dettori, S Shbaklo, N Ambretti, S Gaibani, P Giani, T Coppi, M Bassetti, M De Rosa, FG Marchese, A Cavallo, R Lewis, R Rossolini, GM Viale, P Giannella, M. Clinical consequences of very major errors with semi-automated testing systems for antimicrobial susceptibility of carbapenem-resistant Enterobacterales. Clinical Microbiology and Infections Diseases 2022;8:1290.e1 - 1290.e4.\nLamoth F, Lewis RE, Kontoyiannis DP. Investigational agents for invasive mycoses: A clinical perspective. Clinical Infectious Diseases 2022;75:534-544.\nStemler J, de Jonge N, Skoetz N, Sinkó J, Brüggemann RJ, Busca A, Ben-Ami R, Racil Z, Piechotta V, Lewis R, Cornely OA. Antifungal prophylaxis in adult patients with acute myeloid leukaemia treated with novel targeted therapies: EHA recommendations. The Lancet Haematology 2022;9:e361-e373.\nBrüggemann RJ, Verheggen R, Boerrigter E, Stanzani M, Verweij PE, Blijlevens NMA, Lewis RE. Management of drug–drug interactions of targeted therapies for haematological malignancies and triazole antifungal drugs. The Lancet Haematology. 2022;9(1):e58–72.\nVerweij PE, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Buil JB, Calandra T, Chiller T, Clancy CJ, Cornely OA, Depuydt P, Koehler P, Lagrou K, de Lange D, Lass-Flörl C, Lewis RE, Lortholary O, Liu P-WL, Maertens J, Nguyen MH, Patterson TF, Rijnders BJA, Rodriguez A, Rogers TR, Schouten JA, Wauters J, van de Veerdonk FL, Martin-Loeches I. Taskforce report on the diagnosis and clinical management of COVID-19 associated pulmonary aspergillosis. Intensive Care Medicine. 2021;47(8):819–34.\nStanzani M, Sassi C, Lewis R, Sartor C, Rasetto G, Cavo M, Battista G. Early low-dose computed tomography with pulmonary angiography to improve the early diagnosis of invasive mould disease in patients with haematological malignancies: A pilot study. Journal of Infection. 2021;83(3):371–80.\nRinaldi M, Bartoletti M, Ferrarese A, Franceschini E, Campoli C, Coladonato S, Pascale R, Tedeschi S, Gatti M, Cricca M, Ambretti S, Siniscalchi A, Morelli MC, Cescon M, Cillo U, Di Benedetto F, Burra P, Mussini C, Cristini F, Lewis R, Viale P, Giannella M. Breakthrough invasive fungal infection after liver transplantation in patients on targeted antifungal prophylaxis: A prospective multicentre study. Transplant Infectious Disease [Internet]. 2021;23(4).\nPascale R, Bussini L, Gaibani P, Bovo F, Fornaro G, Lombardo D, Ambretti S, Pensalfine G, Appolloni L, Bartoletti M, Tedeschi S, Tumietto F, Lewis R, Viale P, Giannella M. Carbapenem resistant bacteria in Intensive Care Unit during COVID-19 pandemic: Multicenter before-after cross sectional study. Infection Control and Hospital Epidemiology. 2021\nLamoth F, Lewis RE, Kontoyiannis DP. Navigating the uncertainties of COVID-19–associated aspergillosis: A Comparison With influenza-associated aspergillosis. Journal of Infections Diseases. 2021;224:1631-1640.\nLewis RE, Andes DR. Managing uncertainty in antifungal dosing: antibiograms, therapeutic drug monitoring and drug-drug interactions. Current Opinion in Infectious Diseases. 2021;34(4):288–96.\nLamoth F, Lewis RE, Kontoyiannis DP. Role and interpretation of antifungal susceptibility testing for the management of invasive fungal infections. Journal of Fungi. 2021;7(1):1–21.\nJohnson MD, Lewis RE, Dodds Ashley ES, Perfect JR, Kontoyiannis DP. Reply to Day et al. Journal of Infectious Diseases. 2021;224(9):1627–8.\nGudiol C, Lewis RE, Strati P, Kontoyiannis DP. Chimeric antigen receptor T-cell therapy for the treatment of lymphoid malignancies: is there an excess risk for infection? The Lancet Haematology. 2021;8(3):e216–28.\nGlampedakis E, Cassaing S, Fekkar A, Dannaoui E, Bougnoux M-E, Bretagne S, Neofytos D, Schreiber PW, Hennequin C, Morio F, Shadrivova O, Bongomin F, Fernández-Ruiz M, Bellanger AP, Arikan-Akdagli S, Erard V, Aigner M, Paolucci M, Khanna N, Charpentier E, Bonnal C, Brun S, Gabriel F, Riat A, Zbinden R, Le Pape P, Klimko N, Lewis RE, Richardson M, İnkaya AC, Coste AT, Bochud P-Y, Lamoth F. Invasive aspergillosis due to aspergillus section usti: A multicenter retrospective study. Clinical Infectious Diseases. 2021;72(8):1379–85.\nGiannella M, Freire M, Rinaldi M, Abdala E, Rubin A, Mularoni A, Gruttadauria S, Grossi P, Shbaklo N, Tandoi F, Ferrarese A, Burra P, Fernandes R, Aranha Camargo LF, Asensio A, Alagna L, Bandera A, Simkins J, Abbo L, Halpern M, Santana Girao E, Valerio M, Muñoz P, Fernandez Yunquera A, Statlender L, Yahav D, Franceschini E, Graziano E, Morelli MC, Cescon M, Viale P, Lewis R, Bartoletti M, Pascale R, Campoli C, Coladonato S, Cristini F, Tumietto F, Siniscalchi A, Laici C, Ambretti S, Romagnoli R, De Rosa FG, Muscatello A, Mangioni D, Gori A, Antonelli B, Dondossola D, Rossi G, Invernizzi F, Peghin M, Cillo U, Mussini C, Benedetto FD, Terrabuio DRB, Bittante CD, Toniolo ADR, Balbi E, Garcia JHP, Morrás I, Ramos A, Cruz AF, Salcedo M. Development of a risk prediction model for carbapenem-resistant enterobacteriaceae infection after liver transplantation: A multinational cohort study. Clinical Infectious Diseases. 2021;73(4):E955–66.\nGaibani P, Viciani E, Bartoletti M, Lewis RE, Tonetti T, Lombardo D, Castagnetti A, Bovo F, Horna CS, Ranieri M, Viale P, Re MC, Ambretti S. The lower respiratory tract microbiome of critically ill patients with COVID-19. Scientific Reports [Internet]. 2021;11(1).\nBartoletti M, Pascale R, Cricca M, Rinaldi M, Maccaro A, Bussini L, Fornaro G, Tonetti T, Pizzilli G, Francalanci E, Giuntoli L, Rubin A, Moroni A, Ambretti S, Trapani F, Vatamanu O, Ranieri VM, Castelli A, Baiocchi M, Lewis R, Giannella M, Viale P. Epidemiology of invasive pulmonary aspergillosis among intubated patients with COVID-19: A prospective study. Clinical Infectious Diseases. 2021;73(11):e3606–14.\nAxell-House DB, Wurster S, Jiang Y, Kyvernitakis A, Lewis RE, Tarrand JJ, Raad II, Kontoyiannis DP. Breakthrough mucormycosis developing on mucorales-active antifungals portrays a poor prognosis in patients with hematologic cancer. Journal of Fungi [Internet]. 2021;7(3).\nZaghi I, Gaibani P, Campoli C, Bartoletti M, Giannella M, Ambretti S, Viale P, Lewis RE. Serum bactericidal titres for monitoring antimicrobial therapy: current status and potential role in the management of multidrug-resistant Gram-negative infections. Clinical Microbiology and Infection. 2020;26(10):1338–44.\nVerweij PE, Rijnders BJA, Brüggemann RJM, Azoulay E, Bassetti M, Blot S, Calandra T, Clancy CJ, Cornely OA, Chiller T, Depuydt P, Giacobbe DR, Janssen NAF, Kullberg B-J, Lagrou K, Lass-Flörl C, Lewis RE, Liu PW-L, Lortholary O, Maertens J, Martin-Loeches I, Nguyen MH, Patterson TF, Rogers TR, Schouten JA, Spriet I, Vanderbeke L, Wauters J, van de Veerdonk FL. Review of influenza-associated pulmonary aspergillosis in ICU patients and proposal for a case definition: an expert opinion. Intensive Care Medicine. 2020;46(8):1524–35.\nTolomelli G, Mancuso K, Tacchetti P, Patriarca F, Galli M, Pantani L, Zannetti B, Motta MR, Rizzi S, Dan E, Sinigaglia B, Giudice V, Olmo A, Arpinati M, Chirumbolo G, Fanin R, Lewis RE, Paris L, Bonifazi F, Cavo M, Curti A, Lemoli RM. The timing of plerixafor addition to G-Csf and chemotherapy affects immunological recovery after autologous stem cell transplant in multiple myeloma. Bone Marrow Transplantation. 2020;55(5):946–54.\nLewis RE, Kontoyiannis DP. Infectious disease consultation for candidaemia. The Lancet Infectious Diseases. 2020;20(2):164.\nLewis RE, Kontoyiannis DP. Chimeric antigen receptor T-cell immunotherapy and need for prophylaxis for invasive mold infections. Clinical Infectious Diseases. 2020;71(7):1802–3.\nJohnson MD, Lewis RE, Dodds Ashley ES, Ostrosky-Zeichner L, Zaoutis T, Thompson GR, Andes DR, Walsh TJ, Pappas PG, Cornely OA, Perfect JR, Kontoyiannis DP. Core recommendations for antifungal stewardship: a statement of the mycoses study group education and research consortium. Journal of Infectious Diseases. 2020;222:S175–98.\nGiannella M, Pascale R, Pancaldi L, Monari C, Ianniruberto S, Malosso P, Bussini L, Bartoletti M, Tedeschi S, Ambretti S, Lewis R, Viale P. Follow-up blood cultures are associated with improved outcome of patients with gram-negative bloodstream infections: retrospective observational cohort study. Clinical Microbiology and Infection. 2020;26(7):897–903.\nGarcia-Vidal C, Lewis RE, Kontoyiannis DP. Combination antifungal therapy for breakthrough invasive mould disease in patients with haematological malignancies: When management reasoning eclipses evidence-based medicine. Journal of Antimicrobial Chemotherapy. 2020;75(11):3096–8.\nFernández-Cruz A, Lewis RE, Kontoyiannis DP. How long do we need to treat an invasive mold disease in hematology patients? factors influencing duration of therapy and future questions. Clinical Infectious Diseases. 2020;71(3):685–92.\nCoppola PE, Gaibani P, Sartor C, Ambretti S, Lewis RE, Sassi C, Pignatti M, Paolini S, Curti A, Castagnetti F, Ursi M, Cavo M, Stanzani M. Ceftolozane-tazobactam treatment of hypervirulent multidrug resistant pseudomonas aeruginosa infections in neutropenic patients. Microorganisms. 2020;8(12):1–11.\nBartoletti M, Baldassarre M, Domenicali M, Lewis RE, Giannella M, Antognoli A, Rinaldi M, Zaccherini G, Verucchi G, Marconi L, Tamè M, Berardi S, Napoli L, Siniscalchi A, Fabbri A, Biselli M, Tufoni M, Pavarin RM, Trevisani F, Viale P, Bernardi M, Caraceni P. Prognostic role of bacterial and fungal infections in patients with liver cirrhosis with and without acute-on-chronic liver failure: A prospective 2-Center study. Open Forum Infectious Diseases [Internet]. 2020;7(11).\nZoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild J-J, Trovato L, Lewis RE, Segal E, Rath P-M, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, De La Fuente S, Houbraken J, Risslegger B, Sabino R, Lass-Flörl C, Lackner M. Corrigendum: Azole-resistance in aspergillus terreusand related species: An emerging problem or a rare phenomenon? Frontiers in Microbiology (2018) 9 (516).\nWurster S, Lewis RE, Albert ND, Kontoyiannis DP. Preexposure to isavuconazole increases the virulence of mucorales but not aspergillus fumigatus in a drosophila melanogaster infection model. Antimicrobial Agents and Chemotherapy [Internet]. 2019;63(2).\nWurster S, Kumaresan PR, Albert ND, Hauser PJ, Lewis RE, Kontoyiannis DP. Live monitoring and analysis of fungal growth, viability, and mycelial morphology using the incucyte neurotrack processing module. mBio [Internet]. 2019;10(3).\nWelte T, Len O, Muñoz P, Romani L, Lewis R, Perrella A. Invasive mould infections in solid organ transplant patients: modifiers and indicators of disease and treatment response. Infection. 2019;47(6):919–27.\nWalsh TJ, Lewis RE, Adler-Moore J. Pharmacology of liposomal amphotericin b: An introduction to preclinical and clinical advances for treatment of life-threatening invasive fungal infections. Clinical Infectious Diseases. 2019;68:S241–3.\nStanzani M, Vianelli N, Cavo M, Kontoyiannis DP, Lewis RE. Development and internal validation of a model for predicting 60-day risk of invasive mould disease in patients with haematological malignancies. Journal of Infection. 2019;78(6):484–90.\nStanzani M, Sassi C, Battista G, Lewis RE. Beyond biomarkers: How enhanced CT imaging can improve the diagnostic-driven management of invasive mould disease. Medical Mycology. 2019;57:S274–86.\nStanzani M, Cricca M, Sassi C, Sutto E, De Cicco G, Bonifazi F, Bertuzzi C, Bacci F, Paolini S, Cavo M, Lewis RE. Saprochaete clavata infections in patients undergoing treatment for haematological malignancies: A report of a monocentric outbreak and review of the literature. Mycoses. 2019;62(12):1100–7.\nLewis RE, Wurster S, Beyda ND, Albert ND, Kontoyiannis DP. Comparative in vitro pharmacodynamic analysis of isavuconazole, voriconazole, and posaconazole against clinical isolates of aspergillosis, mucormycosis, fusariosis, and phaeohyphomycosis. Diagnostic Microbiology and Infectious Disease [Internet]. 2019;95(3).\nLewis RE, Kontoyiannis DP, Viale P, Sarpong EM. Using state transition models to explore how the prevalence of subtherapeutic posaconazole exposures impacts the clinical utility of therapeutic drug monitoring for posaconazole tablets and oral suspension. Antimicrobial Agents and Chemotherapy [Internet]. 2019;63(12).\nGroll AH, Rijnders BJA, Walsh TJ, Adler-Moore J, Lewis RE, Brüggemann RJM. Clinical pharmacokinetics, pharmacodynamics, safety and efficacy of liposomal amphotericin b. Clinical Infectious Diseases. 2019;68:S260–74.\nGiannella M, Pascale R, Ferraro G, Toschi A, Pancaldi L, Furii F, Bartoletti M, Tedeschi S, Ambretti S, Lewis RE, Viale P. Risk factors for treatment failure in patients receiving β-lactam/β-lactamase inhibitor combinations for Enterobacteriaceae bloodstream infection: A retrospective, single-centre, cohort study. International Journal of Antimicrobial Agents. 2019;53(5):574–81.\nGiannella M, Bussini L, Pascale R, Bartoletti M, Malagrinò M, Pancaldi L, Toschi A, Ferraro G, Marconi L, Ambretti S, Lewis R, Viale P. Prognostic utility of the new definition of difficult-to-treat resistance among patients with gram-negative bloodstream infections. Open Forum Infectious Diseases [Internet]. 2019;6(12).\nGiannella M, Bartoletti M, Campoli C, Rinaldi M, Coladonato S, Pascale R, Tedeschi S, Ambretti S, Cristini F, Tumietto F, Siniscalchi A, Bertuzzo V, Morelli MC, Cescon M, Pinna AD, Lewis R, Viale P. The impact of carbapenemase-producing Enterobacteriaceae colonization on infection risk after liver transplantation: a prospective observational cohort study. Clinical Microbiology and Infection. 2019;25(12):1525–31.\nGaibani P, Lombardo D, Bartoletti M, Ambretti S, Campoli C, Giannella M, Tedeschi S, Conti M, Mancini R, Landini MP, Re MC, Viale P, Lewis RE. Comparative serum bactericidal activity of meropenem-based combination regimens against extended-spectrum beta-lactamase and KPC-producing Klebsiella pneumoniae. European Journal of Clinical Microbiology and Infectious Diseases. 2019;38(10):1925–31.\nCornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, Hoenigl M, Jensen HE, Lagrou K, Lewis RE, Mellinghoff SC, Mer M, Pana ZD, Seidel D, Sheppard DC, Wahba R, Akova M, Alanio A, Al-Hatmi AMS, Arikan-Akdagli S, Badali H, Ben-Ami R, Bonifaz A, Bretagne S, Castagnola E, Chayakulkeeree M, Colombo AL, Corzo-León DE, Drgona L, Groll AH, Guinea J, Heussel C-P, Ibrahim AS, Kanj SS, Klimko N, Lackner M, Lamoth F, Lanternier F, Lass-Floerl C, Lee D-G, Lehrnbecher T, Lmimouni BE, Mares M, Maschmeyer G, Meis JF, Meletiadis J, Morrissey CO, Nucci M, Oladele R, Pagano L, Pasqualotto A, Patel A, Racil Z, Richardson M, Roilides E, Ruhnke M, Seyedmousavi S, Sidharthan N, Singh N, Sinko J, Skiada A, Slavin M, Soman R, Spellberg B, Steinbach W, Tan BH, Ullmann AJ, Vehreschild JJ, Vehreschild MJGT, Walsh TJ, White PL, Wiederhold NP, Zaoutis T, Chakrabarti A. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. The Lancet Infectious Diseases. 2019;19(12):e405–21.\nBartoletti M, Giannella M, Lewis RE, Caraceni P, Tedeschi S, Paul M, Schramm C, Bruns T, Merli M, Cobos-Trigueros N, Seminari E, Retamar P, Muñoz P, Tumbarello M, Burra P, Cerenzia MT, Barsic B, Calbo E, Maraolo AE, Petrosillo N, Galan-Ladero MA, D’Offizi G, Zak-Doron Y, Rodriguez-Baño J, Baldassarre M, Verucchi G, Domenicali M, Bernardi M, Viale P. Extended infusion of β-lactams for bloodstream infection in patients with liver cirrhosis: An observational multicenter study. Clinical Infectious Diseases. 2019;69(10):1731–9.\nAdler-Moore J, Lewis RE, Brüggemann RJM, Rijnders BJA, Groll AH, Walsh TJ. Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal amphotericin b. Clinical Infectious Diseases. 2019;68:S244–59.\nZoran T, Sartori B, Sappl L, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Cascio GL, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild J-J, Trovato L, Lewis RE, Segal E, Rath P-M, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Uzun O, Roudbary M, de la Fuente S, Houbraken J, Risslegger B, Lass-Flörl C, Lackner M. Azole-resistance in Aspergillus terreus and related species: An emerging problem or a rare Phenomenon? Frontiers in Microbiology [Internet]. 2018;9-17.\nUllmann AJ, Aguado JM, Arikan-Akdagli S, Denning DW, Groll AH, Lagrou K, Lass-Flörl C, Lewis RE, Munoz P, Verweij PE, Warris A, Ader F, Akova M, Arendrup MC, Barnes RA, Beigelman-Aubry C, Blot S, Bouza E, Brüggemann RJM, Buchheidt D, Cadranel J, Castagnola E, Chakrabarti A, Cuenca-Estrella M, Dimopoulos G, Fortun J, Gangneux J-P, Garbino J, Heinz WJ, Herbrecht R, Heussel CP, Kibbler CC, Klimko N, Kullberg BJ, Lange C, Lehrnbecher T, Löffler J, Lortholary O, Maertens J, Marchetti O, Meis JF, Pagano L, Ribaud P, Richardson M, Roilides E, Ruhnke M, Sanguinetti M, Sheppard DC, Sinkó J, Skiada A, Vehreschild MJGT, Viscoli C, Cornely OA. Diagnosis and management of Aspergillus diseases: executive summary of the 2017 ESCMID-ECMM-ERS guideline. Clinical Microbiology and Infection. 2018;24:e1–38.\nTam VH, Pérez C, Ledesma KR, Lewis RE. Transcriptional profiles of pulmonary innate immune responses to isogenic antibiotic-susceptible and multidrug-resistant Pseudomonas aeruginosa. Microbiology and Immunology. 2018;62(4):291–4.\nStanzani M, Lewis RE. Development and applications of prognostic risk models in the management of invasive mold disease. Journal of Fungi [Internet]. 2018;4(4).\nSassi C, Stanzani M, Lewis RE, Facchini G, Bazzocchi A, Cavo M, Battista G. The utility of contrast-enhanced hypodense sign for the diagnosis of pulmonary invasive mould disease in patients with haematological malignancies. British Journal of Radiology [Internet]. 2018;91(1083).\nRizzello I, Castagnetti F, Toschi PG, Bertaccini P, Primavera L, Paolucci M, Faccioli L, Spinardi L, Lewis RE, Cavo M, Stanzani M. Successful treatment of bilateral endogenous Fusarium solani endophthalmitis in a patient with acute lymphocytic leukaemia. Mycoses. 2018;61(1):53–60.\nPea F, Lewis RE. Overview of antifungal dosing in invasive candidiasis. Journal of Antimicrobial Chemotherapy. 2018;73:i33–43.\nMikulska M, Averbuch D, Tissot F, Cordonnier C, Akova M, Calandra T, Ceppi M, Bruzzi P, Viscoli C, Aljurf M, Averbuch D, Barnes R, Blennow O, Bochud P-Y, Bouza E, Bretagne S, Brüggemann R, Carratala J, Cesaro S, Cornely O, Dalianis T, De La Camara R, Donnelly P, Drgona L, Duarte R, Einsele H, Engelhard D, Fox C, Girmenia C, Groll A, Heldal D, Larsen JH, Herbrecht R, Hirsch H, Johnson E, Klyasova G, Koskuenvo M, Lagrou K, Lewis RE, Ljungman P, Maertens J, Maschmeyer G, Nucci M, Padoin C, Pagano L, Pagliuca A, Racil Z, Ribaud P, Rinaldo C, Puechal VR, Roilides E, Robin C, Rovira M, Rupp M, Sanchez S, Schellongowski P, Sedlacek P, Sinko J, Slavin M, Ferreira IS, Styczynski J, Ward K, Witschi A-T. Fluoroquinolone prophylaxis in haematological cancer patients with neutropenia: ECIL critical appraisal of previous guidelines. Journal of Infection. 2018;76(1):20–37.\nLionakis MS, Lewis RE, Kontoyiannis DP. Breakthrough invasive mold infections in the hematology patient: Current concepts and future directions. Clinical Infectious Diseases. 2018;67(10):1621–30.\nGiannella M, Trecarichi EM, Giacobbe DR, De Rosa FG, Bassetti M, Bartoloni A, Bartoletti M, Losito AR, del Bono V, Corcione S, Tedeschi S, Raffaelli F, Saffioti C, Spanu T, Rossolini GM, Marchese A, Ambretti S, Cauda R, Viscoli C, Lewis RE, Viale P, Tumbarello M. Effect of combination therapy containing a high-dose carbapenem on mortality in patients with carbapenem-resistant Klebsiella pneumoniae bloodstream infection. International Journal of Antimicrobial Agents. 2018;51(2):244–8.\nGiannella M, Pascale R, Toschi A, Ferraro G, Graziano E, Furii F, Bartoletti M, Tedeschi S, Ambretti S, Lewis RE, Viale P. Treatment duration for Escherichia coli bloodstream infection and outcomes: retrospective single-centre study. Clinical Microbiology and Infection. 2018;24(10):1077–83.\nGiannella M, Paolucci M, Roncarati G, Vandi G, Pascale R, Trapani F, Bartoletti M, Tedeschi S, Ambretti S, Lewis R, Re MC, Viale P. Potential role of T2Candida in the management of empirical antifungal treatment in patients at high risk of candidaemia: A pilot single-centre study. Journal of Antimicrobial Chemotherapy. 2018;73(10):2856–9.\nGaibani P, Campoli C, Lewis RE, Volpe SL, Scaltriti E, Giannella M, Pongolini S, Berlingeri A, Cristini F, Bartoletti M, Tedeschi S, Ambretti S. In vivo evolution of resistant subpopulations of KPC-producing Klebsiella pneumoniae during ceftazidime/avibactam treatment. Journal of Antimicrobial Chemotherapy. 2018;73(6):1525–9.\nFernandez IJ, Crocetta FM, Demattè M, Farneti P, Stanzani M, Lewis RE, Fornaciari M, Pasquini E, Sciarretta V. Acute invasive fungal rhinosinusitis in immunocompromised patients: Role of an early diagnosis. Otolaryngology - Head and Neck Surgery (United States). 2018;159(2):386–93.\nDi Blasi R, Cattaneo C, Lewis RE, Tumbarello M, Angelici L, Dragonetti G, Busca A, Cambò B, Candoni A, Cesarini M, Cesaro S, Delia M, Fanci R, Farina F, Garzia M, Giordano A, Martino B, Melillo L, Nadali G, Perriello V, Picardi M, Quinto AM, Salutari P, Spolzino A, Vacca A, Vetro C, Zancanella M, Nosari A, Aversa F, Pagano L. Febrile events in acute lymphoblastic leukemia: a prospective observational multicentric SEIFEM study (SEIFEM-2012/B ALL). Annals of Hematology. 2018;97(5):791–8.\nCesaro S, Dalianis T, Rinaldo CH, Koskenvuo M, Pegoraro A, Einsele H, Cordonnier C, Hirsch HH, Akova M, Aljurf M, Averbuch D, Barnes R, Blennow O, Bochud P-Y, Bouza E, Bretagne S, Brüggemann R, Calandra T, Carratala J, Cornely O, de la Camara R, Donnelly P, Drgona L, Duarte R, Engelhard D, Fox C, Girmenia C, Groll A, Heldal D, Helweg-Larsen J, Herbrecht R, Johnson E, Klyasova G, Lagrou K, Lewis RE, Ljungman P, Maertens J, Mikulska M, Nucci M, Padoin C, Pagano L, Pagliuca A, Racil Z, Ribaud P, Rizzi-Puechal V, Roilides E, Robin C, Rovira M, Rupp M, Sanchez S, Schellongowski P, Sedlacek P, Sinko J, Slavin M, Ferreira IS, Styczynski J, Tissot F, Viscoli C, Ward K, Witschi A-T. ECIL guidelines for the prevention, diagnosis and treatment of BK polyomavirus-associated haemorrhagic cystitis in haematopoietic stem cell transplant recipients. Journal of Antimicrobial Chemotherapy. 2018;73(1):12–21.\nBartoletti M, Tedeschi S, Pascale R, Raumer L, Maraolo AE, Palmiero G, Tumietto F, Cristini F, Ambretti S, Giannella M, Lewis RE, Viale P. Differences in the rate of carbapenem-resistant Enterobacteriaceae colonisation or Clostridium difficile infection following frontline treatment with tigecycline vs. meropenem for intra-abdominal infections. International Journal of Antimicrobial Agents. 2018;51(3):516–21.\nBartoletti M, Lewis RE, Giannella M, Tedeschi S, Viale P. The role of extended infusion β-lactams in the treatment of bloodstream infections in patients with liver cirrhosis. Expert Review of Anti-Infective Therapy. 2018;16(10):771–9.\nBartoletti M, Giannella M, Lewis R, Caraceni P, Tedeschi S, Paul M, Schramm C, Bruns T, Merli M, Cobos-Trigueros N, Seminari E, Retamar P, Muñoz P, Tumbarello M, Burra P, Torrani Cerenzia M, Barsic B, Calbo E, Maraolo AE, Petrosillo N, Galan-Ladero MA, D’Offizi G, Bar Sinai N, Rodríguez-Baño J, Verucchi G, Bernardi M, Viale P, Campoli C, Siccardi G, Ambretti S, Stallmach A, Venditti M, Lucidi C, Ludovisi S, De Cueto M, Navarro MD, Lopez Cortes E, Bouza E, Valerio M, Eworo A, Losito R, Senzolo M, Nadal E, Ottobrelli A, Varguvic M, Badia C, Borgia G, Gentile I, Buonomo AR, Boumis E, Beteta-Lopez A, Rianda A, Taliani G, Grieco S. A prospective multicentre study of the epidemiology and outcomes of bloodstream infection in cirrhotic patients. Clinical Microbiology and Infection. 2018;24(5):546.e1-546.e8.\nStanzani M, Vianelli N, Cavo M, Maritati A, Morotti M, Lewis RE. Retrospective cohort analysis of liposomal amphotericin b nephrotoxicity in patients with hematological malignancies. Antimicrobial Agents and Chemotherapy [Internet]. 2017;61(9).\nSassi C, Stanzani M, Lewis RE, Vianelli N, Tarsi A, Poerio A, Cavo M, Battista G. Radiologic findings of Fusarium pneumonia in neutropenic patients. Mycoses. 2017;60(2):73–8.\nRisslegger B, Zoran T, Lackner M, Aigner M, Sánchez-Reus F, Rezusta A, Chowdhary A, Taj-Aldeen SJ, Arendrup MC, Oliveri S, Kontoyiannis DP, Alastruey-Izquierdo A, Lagrou K, Lo Cascio G, Meis JF, Buzina W, Farina C, Drogari-Apiranthitou M, Grancini A, Tortorano AM, Willinger B, Hamprecht A, Johnson E, Klingspor L, Arsic-Arsenijevic V, Cornely OA, Meletiadis J, Prammer W, Tullio V, Vehreschild J-J, Trovato L, Lewis RE, Segal E, Rath P-M, Hamal P, Rodriguez-Iglesias M, Roilides E, Arikan-Akdagli S, Chakrabarti A, Colombo AL, Fernández MS, Martin-Gomez MT, Badali H, Petrikkos G, Klimko N, Heimann SM, Houbraken J, Uzun O, Edlinger M, Fuente SDL, Lass-Flörl C. A prospective international Aspergillus terreus survey: an EFISG, ISHAM and ECMM joint study. Clinical Microbiology and Infection. 2017;23(10):776.e1-776.e5.\nPolverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, Sabattini E, Riminucci M, Godio L, Catani L, Nicolosi M, Perricone M, Sollazzo D, Colafigli G, Campana A, Merli F, Vitolo U, Alimena G, Martinelli G, Lewis RE, Vianelli N, Cavo M, Palandri F. Risk factors for infections in myelofibrosis: role of disease status and treatment. A multicenter study of 507 patients. American Journal of Hematology. 2017;92(1):37–41.\nPierro A, Ficarelli S, Ayhan N, Morini S, Raumer L, Bartoletti M, Mastroianni A, Prati F, Schivazappa S, Cenni P, Vocale C, Rossini G, Gaibani P, Sambri V, Landini MP, Lewis RE, Charrel RN, Varani S. Characterization of antibody response in neuroinvasive infection caused by Toscana virus. Clinical Microbiology and Infection. 2017;23(11):868–73.\nLewis RE, Verweij PE. Animal models for studying triazole resistance in aspergillus fumigatus. Journal of Infectious Diseases. 2017;216:S466–73.\nLewis RE. Using carbapenems for carbapenem-resistant Klebsiella pneumoniae-Are we flogging a dead (work)horse antibiotic? Virulence. 2017;8(1):13–4.\nHeo ST, Tatara AM, Jiménez-Ortigosa C, Jiang Y, Lewis RE, Tarrand J, Tverdek F, Albert ND, Verweij PE, Meis JF, Mikos AG, Perlin DS, Kontoyiannis DP. Changes in in vitro susceptibility patterns of aspergillus to triazoles and correlation with aspergillosis outcome in a tertiary care cancer center, 1999-2015. Clinical Infectious Diseases. 2017;65(2):216–25.\nGiannella M, Graziano E, Marconi L, Girometti N, Bartoletti M, Tedeschi S, Tumietto F, Cristini F, Ambretti S, Berlingeri A, Lewis RE, Viale P. Risk factors for recurrent carbapenem resistant Klebsiella pneumoniae bloodstream infection: a prospective cohort study. European Journal of Clinical Microbiology and Infectious Diseases. 2017;36(10):1965–70.\nGaibani P, Lewis RE, Volpe SL, Giannella M, Campoli C, Landini MP, Viale P, Re MC, Ambretti S. In vitro interaction of ceftazidime–avibactam in combination with different antimicrobials against KPC-producing Klebsiella pneumoniae clinical isolates. International Journal of Infectious Diseases. 2017;65:1–3.\nBartoletti M, Martelli G, Tedeschi S, Morelli M, Bertuzzo V, Tadolini M, Pianta P, Cristini F, Giannella M, Lewis RE, Pinna AD, Viale P. Liver transplantation is associated with good clinical outcome in patients with active tuberculosis and acute liver failure due to anti-tubercular treatment. Transplant Infectious Disease [Internet]. 2017;19(2).\nStanzani M, Sassi C, Battista G, Cavo M, Lewis RE. Improved radiographic imaging of invasive fungal disease: The cornerstone to antifungal stewardship in the hematology units? Current Fungal Infection Reports. 2016;10(2):78–86.\nPotenza L, Vallerini D, Barozzi P, Riva G, Gilioli A, Forghieri F, Candoni A, Cesaro S, Quadrelli C, Maertens J, Rossi G, Morselli M, Codeluppi M, Mussini C, Colaci E, Messerotti A, Paolini A, Maccaferri M, Fantuzzi V, Del Giovane C, Stefani A, Morandi U, Maffei R, Marasca R, Narni F, Fanin R, Comoli P, Romani L, Beauvais A, Viale PL, Latgè JP, Lewis RE, Luppi M. Mucorales-specific T cells in patients with hematologic malignancies. PLoS ONE [Internet]. 2016;11(2).\nMaschmeyer G, Helweg-Larsen J, Pagano L, Robin C, Cordonnier C, Schellongowski P, Akova M, Aljurf M, Averbuch D, Barnes R, Blennow O, Bochud P-Y, Bouza E, Bretagne S, Brüggemann R, Calandra T, Carratalà J, Cesaro S, Cordonnier C, Cornely O, Dalianis T, De La Camara R, Donnelly P, Drgona L, Duarte R, Einsele H, Engelhard D, Fox C, Girmenia C, Groll A, Heldal D, Helweg-Larsen J, Herbrecht R, Hirsch H, Johnson E, Klyasova G, Koskuenvo M, Lagrou K, Lewis RE, Ljungman P, Maertens J, Maschmeyer G, Mikulska M, Nucci M, Padoin C, Dwe ALLW, Pagliuca A, Racil Z, Ribaud P, Rinaldo C, Rizzi-Puechal V, Roilides E, Robin C, Rovira M, Rupp M, Sanchez S, Schellongowski P, Sedlacek P, Sinko J, Slavin M, Ferreira IS, Styczynski J, Tissot F, Viscoli C, Ward K, Witschi A-T. ECIL guidelines for treatment of Pneumocystis jirovecii pneumonia in non-HIV-infected haematology patients. Journal of Antimicrobial Chemotherapy. 2016;71(9):2405–13.\nKyvernitakis A, Torres HA, Jiang Y, Chamilos G, Lewis RE, Kontoyiannis DP. Initial use of combination treatment does not impact survival of 106 patients with haematologic malignancies and mucormycosis: a propensity score analysis. Clinical Microbiology and Infection. 2016;22(9):811.e1-811.e8.\nGiannella M, Bartoletti M, Morelli M, Cristini F, Tedeschi S, Campoli C, Tumietto F, Bertuzzo V, Ercolani G, Faenza S, Pinna AD, Lewis RE, Viale P. Antifungal prophylaxis in liver transplant recipients: one size does not fit all. Transplant Infectious Disease. 2016;18(4):538–44.\nCurti A, Ruggeri L, Parisi S, Bontadini A, Dan E, Motta MR, Rizzi S, Trabanelli S, Ocadlikova D, Lecciso M, Giudice V, Fruet F, Urbani E, Papayannidis C, Martinelli G, Bandini G, Bonifazi F, Lewis RE, Cavo M, Velardi A, Lemoli RM. Larger size of donor alloreactive NK cell repertoire correlates with better response to NK cell immunotherapy in elderly acute myeloid leukemia patients. Clinical Cancer Research. 2016;22(8):1914–21.\nBellanger A-P, Tatara AM, Shirazi F, Gebremariam T, Albert ND, Lewis RE, Ibrahim AS, Kontoyiannis DP. Statin concentrations below the minimum inhibitory concentration attenuate the virulence of rhizopus oryzae. Journal of Infectious Diseases. 2016;214(1):114–21.\nBartoletti M, Giannella M, Lewis RE, Viale P. Bloodstream infections in patients with liver cirrhosis. Virulence. 2016;7(3):309–19.\nViale P, Tumietto F, Giannella M, Bartoletti M, Tedeschi S, Ambretti S, Cristini F, Gibertoni C, Venturi S, Cavalli M, De Palma A, Puggioli MC, Mosci D, Callea E, Masina R, Moro ML, Lewis RE. Impact of a hospital-wide multifaceted programme for reducing carbapenem-resistant Enterobacteriaceae infections in a large teaching hospital in northern Italy. Clinical Microbiology and Infection. 2015;21(3):242–7.\nViale P, Scudeller L, Pea F, Tedeschi S, Lewis R, Bartoletti M, Sbrojavacca R, Cristini F, Tumietto F, Di Lauria N, Fasulo G, Giannella M. Implementation of a meningitis care bundle in the emergency room reduces mortality associated with acute bacterial meningitis. Annals of Pharmacotherapy. 2015;49(9):978–85.\nViale P, Giannella M, Tedeschi S, Lewis R. Treatment of MDR-Gram negative infections in the 21st century: a never ending threat for clinicians. Current Opinion in Pharmacology. 2015;24:30–7.\nViale P, Giannella M, Bartoletti M, Tedeschi S, Lewis R. Considerations about antimicrobial stewardship in settings with epidemic extended-spectrum β-Lactamase-Producing or carbapenem-resistant enterobacteriaceae. Infectious Diseases and Therapy. 2015;4:65–83.\nStanzani M, Sassi C, Lewis RE, Tolomelli G, Bazzocchi A, Cavo M, Vianelli N, Battista G. High resolution computed tomography angiography improves the radiographic diagnosis of invasive mold disease in patients with hematological malignancies. Clinical Infectious Diseases. 2015;60(11):1603–10.\nShirazi F, Lewis RE, Kontoyiannis DP. Micafungin induced apoptosis in candida parapsilosis independent of its susceptibility to micafungin. Microbial Cell. 2015;2(11):445–50.\nSassi C, Stanzani M, Lewis RE. Computerized tomographic pulmonary angiography discriminates invasive mould disease of the lung from lymphoma. British Journal of Haematology. 2015;169(4):462–462.\nLewis RE, Giannella M, Viale P. Serum galactomannan diagnosis of breakthrough invasive fungal disease. Clinical Infectious Diseases. 2015;60(8):1284.\nKontoyiannis DP, Lewis RE. Treatment principles for the management of mold infections. Cold Spring Harbor Perspectives in Medicine [Internet]. 2015;5(4).\nGiannella M, Ercolani G, Cristini F, Morelli M, Bartoletti M, Bertuzzo V, Tedeschi S, Faenza S, Puggioli C, Lewis RE, Pinna AD, Viale P. High-dose weekly liposomal amphotericin B antifungal prophylaxis in patients undergoing liver transplantation: A prospective phase II trial. Transplantation. 2015;99(4):848–54.\nGiannella M, Bartoletti M, Morelli MC, Tedeschi S, Cristini F, Tumietto F, Pasqualini E, Danese I, Campoli C, Lauria ND, Faenza S, Ercolani G, Lewis R, Pinna AD, Viale P. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: The importance of pre- and posttransplant colonization. American Journal of Transplantation. 2015;15(6):1708–15.\nBeyda ND, Liao G, Endres BT, Lewis RE, Garey KW. Innate inflammatory response and immunopharmacologic activity of micafungin, caspofungin, and voriconazole against wild-type and FKS mutant Candida glabrata isolates. Antimicrobial Agents and Chemotherapy. 2015;59(9):5405–12.\nBellanger A-P, Albert ND, Lewis RE, Walsh TJ, Kontoyiannis DP. Effect of preexposure to triazoles on susceptibility and virulence of Rhizopus oryzae. Antimicrobial Agents and Chemotherapy. 2015;59(12):7830–2.\nTascini C, Sbrana F, Flammini S, Tagliaferri E, Arena F, Leonildi A, Ciullo I, Amadori F, Di Paolo A, Ripoli A, Lewis R, Rossolini GM, Menichetti F, Lambelet P, Forfori F, Viaggi B, Papini F, Urbani L, Malacarne P. Oral gentamicin gut decontamination for prevention of KPC-producing Klebsiella pneumoniae infections: Relevance of concomitant systemic antibiotic therapy. Antimicrobial Agents and Chemotherapy. 2014;58(4):1972–6.\nLewis RE, Liao G, Young K, Douglas C, Kontoyiannis DP. Macrophage reporter cell assay for screening immunopharmacological activity of cell wall-active antifungals. Antimicrobial Agents and Chemotherapy. 2014;58(3):1738–43.\nLewis RE, Georgiadou SP, Sampsonas F, Chamilos G, Kontoyiannis DP. Risk factors for early mortality in haematological malignancy patients with pulmonary mucormycosis. Mycoses. 2014;57(1):49–55.\nLewis RE, Albert ND, Kontoyiannis DP. Comparative pharmacodynamics of posaconazole in neutropenic murine models of invasive pulmonary aspergillosis and mucormycosis. Antimicrobial Agents and Chemotherapy. 2014;58(11):6767–72.\nKontoyiannis DP, Lewis RE. Reply to “Risk for invasive fungal infections during acute myeloid leukemia induction therapy: A true association with echinocandins?” Antimicrobial Agents and Chemotherapy. 2014;58(8):4990–1.\nGomes MZR, Mulanovich VE, Jiang Y, Lewis RE, Kontoyiannis DP. Incidence density of invasive fungal infections during primary antifungal prophylaxis in newly diagnosed acute myeloid leukemia patients in a tertiary cancer center, 2009 to 2011. Antimicrobial Agents and Chemotherapy. 2014;58(2):865–73.\nGomes MZR, Jiang Y, Mulanovich VE, Lewis RE, Kontoyiannis DP. Effectiveness of primary anti-Aspergillus prophylaxis during remission induction chemotherapy of acute myeloid leukemia. Antimicrobial Agents and Chemotherapy. 2014;58(5):2775–80.\nGirometti N, Lewis RE, Giannella M, Ambretti S, Bartoletti M, Tedeschi S, Tumietto F, Cristini F, Trapani F, Gaibani P, Viale P. Klebsiella pneumoniae bloodstream infection epidemiology and impact of inappropriate empirical therapy. Medicine (United States). 2014;93(17):298–308.\nGiannella M, Trecarichi EM, De Rosa FG, Del Bono V, Bassetti M, Lewis RE, Losito AR, Corcione S, Saffioti C, Bartoletti M, Maiuro G, Cardellino CS, Tedeschi S, Cauda R, Viscoli C, Viale P, Tumbarello M. Risk factors for carbapenem-resistant Klebsiella pneumoniae bloodstream infection among rectal carriers: A prospective observational multicentre study. Clinical Microbiology and Infection. 2014;20(12):1357–62.\nGiannella M, Morelli MC, Cristini F, Ercolani G, Cescon M, Bartoletti M, Tedeschi S, Pasqualini E, Lewis RE, Pinna AD, Viale P. Carbapenem-resistant Klebsiella pneumoniae colonization at liver transplantation: A management challenge. Liver Transplantation. 2014;20(5):631–3.\nGaibani P, Lombardo D, Lewis RE, Mercuri M, Bonora S, Landini MP, Ambretti S. In vitro activity and post-antibiotic effects of colistin in combination with other antimicrobials against colistin-resistant KPC-producing Klebsiella pneumoniae bloodstream isolates. Journal of Antimicrobial Chemotherapy. 2014;69(7):1856–65.\nDimopoulou D, Hamilos G, Tzardi M, Lewis RE, Samonis G, Kontoyiannis DP. Anidulafungin versus caspofungin in a mouse model of candidiasis caused by anidulafungin-Susceptible candida parapsilosis isolates with different degrees of caspofungin susceptibility. Antimicrobial Agents and Chemotherapy. 2014;58(1):229–36.\nDi Paolo A, Polillo M, Tascini C, Lewis R, Menichetti F, Danesi R. Different recommendations for daptomycin dosing over time in patients with severe infections. Clinical Infectious Diseases. 2014;58(12):1788–9.\nBartoletti M, Giannella M, Caraceni P, Domenicali M, Ambretti S, Tedeschi S, Verucchi G, Badia L, Lewis RE, Bernardi M, Viale P. Epidemiology and outcomes of bloodstream infection in patients with cirrhosis. Journal of Hepatology. 2014;61(1):51–8.\nViale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Review of Anti-Infective Therapy. 2013;11(10):1053–63.\nTascini C, Tagliaferri E, Giani T, Leonildi A, Flammini S, Casini B, Lewis R, Ferranti S, Rossolini GM, Menichetti F. Synergistic activity of colistin plus rifampin against colistin-resistant kpc-producing klebsiella pneumoniae. Antimicrobial Agents and Chemotherapy. 2013;57(8):3990–3.\nStanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, Ambretti S, Baccarani M, Cavo M, Vianelli N. A risk prediction score for invasive mold disease in patients with hematological malignancies. PLoS ONE [Internet]. 2013;8(9).\nShirazi F, Pontikos MA, Walsh TJ, Albert N, Lewis RE, Kontoyiannis DP. Hyperthermia sensitizes rhizopus oryzae to posaconazole and itraconazole action through apoptosis. Antimicrobial Agents and Chemotherapy. 2013;57(9):4360–8.\nPetrosillo N, Giannella M, Lewis R, Viale P. Treatment of carbapenem-resistant Klebsiella pneumoniae: The state of the art. Expert Review of Anti-Infective Therapy. 2013;11(2):159–77.\nPaolucci M, Stanzani M, Melchionda F, Tolomelli G, Castellani G, Landini MP, Varani S, Lewis RE, Sambri V. Routine use of a real-time polymerase chain reaction method for detection of bloodstream infections in neutropaenic patients. Diagnostic Microbiology and Infectious Disease. 2013;75(2):130–4.\nLewis RE, Kontoyiannis DP. Epidemiology and treatment of mucormycosis. Future Microbiology. 2013;8(9):1163–75.\nLewis RE, Cahyame-Zuniga L, Leventakos K, Chamilos G, Ben-Ami R, Tamboli P, Tarrand J, Bodey GP, Luna M, Kontoyiannis DP. Epidemiology and sites of involvement of invasive fungal infections in patients with haematological malignancies: A 20-year autopsy study. Mycoses. 2013;56(6):638–45.\nLewis RE, Ben-Ami R, Best L, Albert N, Walsh TJ, Kontoyiannis DP. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis. Journal of Infectious Diseases. 2013;207(5):834–41.\nLewis RE, Albert NP, Liao G, Wang W, Prince RA, Kontoyiannis DP. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia. Journal of Antimicrobial Chemotherapy. 2013;68(5):1148–51.\nKontoyiannis DP, Georgiadou SP, Wierda WG, Wright S, Albert ND, Ferrajoli A, Keating M, Lewis RE. Impaired bactericidal but not fungicidal activity of polymorphonuclear neutrophils in patients with chronic lymphocytic leukemia. Leukemia and Lymphoma. 2013;54(8):1730–3.\nGirardis M, Bassetti M, Lewis RE, Viale P. Aggressive versus conservative initiation of antibiotics. The Lancet Infectious Diseases. 2013;13(5):387.\nGeorgiadou SP, Lewis RE, Best L, Torres HA, Champlin RE, Kontoyiannis DP. The impact of prior invasive mold infections in leukemia patients who undergo allo-SCT in the era of triazole-based secondary prophylaxis. Bone Marrow Transplantation. 2013;48(1):141–3.\nBeyda ND, Regen S, Lewis RE, Garey KW. Immunomodulatory agents as adjunctive therapy for the treatment of resistant Candida species. Current Fungal Infection Reports. 2013;7(2):119–25.\nBen-Ami R, Watson CC, Lewis RE, Albert ND, Arias CA, Raad II, Kontoyiannis DP. Drosophila melanogaster as a model to explore the effects of methicillin-resistant Staphylococcus aureus strain type on virulence and response to linezolid treatment. Microbial Pathogenesis. 2013;55(1):16–20.\nBen-Ami R, Albert ND, Lewis RE, Kontoyiannis DP. Proangiogenic growth factors potentiate in situ angiogenesis and enhance antifungal drug activity in murine invasive aspergillosis. Journal of Infectious Diseases. 2013;207(7):1066–74.\nStanzani M, Battista G, Sassi C, Lewis RE, Tolomelli G, Clissa C, Femia R, Bazzocchi A, Tumietto F, Viale P, Ambretti S, Baccarani M, Vianelli N. Computed tomographic pulmonary angiography for diagnosis of invasive mold diseases in patients with hematological malignancies. Clinical Infectious Diseases. 2012;54(5):610–6.\nSpellberg B, Ibrahim A, Roilides E, Lewis RE, Lortholary O, Petrikkos G, Kontoyiannis DP, Walsh TJ. Combination therapy for mucormycosis: Why, what, and how? Clinical Infectious Diseases. 2012;54(SUPPL. 1):S73–8.\nMuhammed M, Feldmesser M, Shubitz LF, Lionakis MS, Sil A, Wang Y, Glavis-Blom J, Lewis RE, Galgiani J, Casadevall A, Kontoyiannis DP, Mylonakis E. Mouse models for the study of fungal pneumonia: A collection of detailed experimental protocols for the study of Coccidioides, Cryptococcus, Fusarium, Histoplasma and combined infection due to Aspergillus-Rhizopus. Virulence. 2012;3(3):15.\nLewis RE, Viale P, Kontoyiannis DP. The potential impact of antifungal drug resistance mechanisms on the host immune response to Candida. Virulence. 2012;3(4):368–76.\nLewis RE, Viale P. Update on amphotericin B pharmacology and dosing for common systemic mycoses. Current Fungal Infection Reports. 2012;6(4):349–57.\nLewis RE, Lortholary O, Spellberg B, Roilides E, Kontoyiannis DP, Walsh TJ. How does antifungal pharmacology differ for mucormycosis versus aspergillosis? Clinical Infectious Diseases. 2012;54(SUPPL. 1):S67–72.\nLewis RE. Importance of pharmacokinetic considerations for selecting therapy in the treatment of invasive fungal infections. American Journal of Therapeutics. 2012;19(1):51–63.\nKontoyiannis DP, Lewis RE, Lotholary O, Spellberg B, Petrikkos G, Roillides E, Ibrahim A, Walsh TJ. Future directions in mucormycosis research. Clinical Infectious Diseases. 2012;54(SUPPL. 1):S79–85.\nJulius JM, Gaikwad A, Lowry A, Lewis RE, Lozano RD, Dalrymple JL, Coleman RL, Smith JA. Defining the role of echinocandin catechol functional groups in the development of secondary hepatocellular carcinoma. Journal of Antimicrobial Chemotherapy. 2012;67(2):422–9.\nGeorgiadou SP, Pongas G, Fitzgerald NE, Lewis RE, Rytting M, Marom EM, Kontoyiannis DP. Invasive mold infections in pediatric cancer patients reflect heterogeneity in etiology, presentation, and outcome: A 10-year, single-institution, retrospective study. Journal of the Pediatric Infectious Diseases Society. 2012;1(2):125–35.\nChitasombat MN, Kofteridis DP, Jiang Y, Tarrand J, Lewis RE, Kontoyiannis DP. Rare opportunistic (non-Candida, non-Cryptococcus) yeast bloodstream infections in patients with cancer. Journal of Infection. 2012;64(1):68–75.\nChavan NL, Young JK, Drezek RA, Lewis R, Bikram M. Interactions of liposome carriers with infectious fungal hyphae reveals the role of β-glucans. Molecular Pharmaceutics. 2012;9(9):2489–96.\nCahuayme-Zuniga L, Lewis RE, Mulanovich VE, Kontoyiannis DP. Weekly liposomal amphotericin B as secondary prophylaxis for invasive fungal infections in patients with hematological malignancies. Medical Mycology. 2012;50(5):543–8.\nBeyda ND, Lewis RE, Garey KW. Echinocandin resistance in Candida species: Mechanisms of reduced susceptibility and therapeutic approaches [Resistencia a equinocandinas en especies de candida: Mecanismos de susceptibilidad reducida y alternativas terapéuticas]. Annals of Pharmacotherapy. 2012;46(7–8):1086–96.\nLewis RE, Pongas GN, Albert N, Ben-Ami R, Walsh TJ, Kontoyiannis DP. Activity of deferasirox in Mucorales: Influences of species and exogenous iron. Antimicrobial Agents and Chemotherapy. 2011;55(1):411–3.\nLewis RE, Liao G, Wang W, Prince RA, Kontoyiannis DP. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection. Virulence. 2011;2(4):348–55.\nLewis RE, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative in vivo dose-dependent activity of caspofungin and anidulafungin against echinocandin-susceptible and -resistant Aspergillus fumigatus. Journal of Antimicrobial Chemotherapy. 2011;66(6):1324–31.\nLewis RE, Leventakos K, Liao G, Kontoyiannis DP. Efficacy of caspofungin in neutropenic and corticosteroid-immunosuppressed murine models of invasive pulmonary mucormycosis. Antimicrobial Agents and Chemotherapy. 2011;55(7):3584–7.\nLewis RE. Pharmacokinetic-pharmacodynamic optimization of triazole antifungal therapy. Current Opinion in Infectious Diseases. 2011;24(SUPPL. 2):S14–29.\nLewis RE. Cutaneous mucormycosis in tornado survivors. Current Fungal Infection Reports. 2011;5(4):187–9.\nLewis RE. Current concepts in antifungal pharmacology. Mayo Clinic Proceedings. 2011;86(8):805–17.\nKontoyiannis DP, Lewis RE. How I treat mucormycosis. Blood. 2011;118(5):1216–24.\nGomes MZR, Lewis RE, Kontoyiannis DP. Mucormycosis caused by unusual mucormycetes, non-Rhizopus, -Mucor, and -Lichtheimia species. Clinical Microbiology Reviews. 2011;24(2):411–45.\nChen SC-A, Lewis RE, Kontoyiannis DP. Direct effects of non-antifungal agents used in cancer chemotherapy and organ transplantation on the development and virulence of Candida and Aspergillus species. Virulence [Internet]. 2011;2(4).\nBen-Ami R, Lewis RE, Kontoyiannis DP. In vitro interactions among echinocandins against Aspergillus fumigatus: Lack of concordance among methods. Medical Mycology. 2011;49(3):285–8.\nBen-Ami R, Garcia-Effron G, Lewis RE, Gamarra S, Leventakos K, Perlin DS, Kontoyiannis DP. Fitness and virulence costs of Candida albicans FKS1 hot spot mutations associated with echinocandin resistance. Journal of Infectious Diseases. 2011;204(4):626–35.\nMilito MA, Kontoyiannis DP, Lewis RE, Liu P, Mawlawi OR, Truong MT, Marom EM. Influence of host immunosuppression on CT findings in invasive pulmonary aspergillosis. Medical Mycology. 2010;48(6):817–23.\nLewis RE, Albert ND, Liao G, Hou J, Prince RA, Kontoyiannis DP. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis. Antimicrobial Agents and Chemotherapy. 2010;54(3):1298–304.\nLewis RE. Antifungal therapeutic drug monitoring. Current Fungal Infection Reports. 2010;4(3):158–67.\nLeventakos K, Lewis RE, Kontoyiannis DP. Fungal infections in leukemia patients: How do we prevent and treat them? Clinical Infectious Diseases. 2010;50(3):405–15.\nKontoyiannis DP, Lewis RE. Studying fungal pathogenesis in Drosophila. Microbe. 2010;5(7):291–6.\nEvans SE, Scott BL, Clement CG, Larson DT, Kontoyiannis D, Lewis RE, Lasala PR, Pawlik J, Peterson JW, Chopra AK, Klimpel G, Bowden G, Höök M, Xu Y, Tuvim MJ, Dickey BF. Stimulated innate resistance of lung epithelium protects mice broadly against bacteria and fungi. American Journal of Respiratory Cell and Molecular Biology. 2010;42(1):40–50.\nEvans SE, Leventakos K, Ben-Ami R, You D, Thakkar SG, Lewis RE, Kontoyiannis DP. Toll-deficient Drosophila are resistant to infection by Pneumocystis spp. additional evidence of specificity to mammalian hosts. Virulence. 2010;1(6):523–5.\nChamilos G, Bignell EM, Schrettl M, Lewis RE, Leventakos K, May GS, Haas H, Kontoyiannis DP. Exploring the concordance of aspergillus fumigatus pathogenicity in mice and Toll-deficient flies. Medical Mycology. 2010;48(3):506–10.\nCampo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancies at a cancer center: 1998-2009. Journal of Infection. 2010;60(5):331–7.\nBen-Ami R, Varga J, Lewis RE, May GS, Nierman WC, Kontoyiannis DP. Characterization of a 5-azacytidine-induced developmental Aspergillus fumigatus variant. Virulence. 2010;1(3):164–73.\nBen-Ami R, Lewis RE, Tarrand J, Leventakos K, Kontoyiannis DP. Antifungal activity of colistin against Mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection. Antimicrobial Agents and Chemotherapy. 2010;54(1):484–90.\nBen-Ami R, Lewis RE, Leventakos K, Latgé J-P, Kontoyiannis DP. Cutaneous model of invasive aspergillosis. Antimicrobial Agents and Chemotherapy. 2010;54(5):1848–54.\nBen-Ami R, Lewis RE, Kontoyiannis DP. Enemy of the (immunosuppressed) state: An update on the pathogenesis of Aspergillus fumigatus infection. British Journal of Haematology. 2010;150(4):406–17.\nBen-Ami R, LaSala PR, Lewis RE, Kontoyiannis DP. Lack of galactomannan reactivity in dematiaceous molds recovered from cancer patients with phaeohyphomycosis. Diagnostic Microbiology and Infectious Disease. 2010;66(2):200–3.\nBen-Ami R, Lamaris GA, Lewis RE, Kontoyiannis DP. Interstrain variability in the virulence of Aspergillus fumigatus and Aspergillus terreus in a Toll-deficient Drosophila fly model of invasive aspergillosis. Medical Mycology. 2010;48(2):310–7.\nWiederhold NP, Lewis RE. Antifungal activity against Scedosporium species and novel assays to assess antifungal pharmacodynamics against filamentous fungi. Medical Mycology. 2009;47(4):422–32.\nTam VH, Ledesma KR, Schilling AN, Lim T-P, Yuan Z, Ghose R, Lewis RE. In vivo dynamics of carbapenem-resistant Pseudomonas aeruginosa selection after suboptimal dosing. Diagnostic Microbiology and Infectious Disease. 2009;64(4):427–33.\nSipsas NV, Lewis RE, Tarrand J, Hachem R, Rolston KV, Raad II, Kontoyiannis DP. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): Stable incidence but changing epidemiology of a still frequently lethal infection. Cancer. 2009;115(20):4745–52.\nSipsas NV, Lewis RE, Raad II, Kontoyiannis DP. Monotherapy with caspofungin for candidaemia in adult patients with cancer: a retrospective, single institution study. International Journal of Antimicrobial Agents. 2009;34(1):95–8.\nRoussos P, Lewis RE, Kontoyiannis DP. Azoles and antidepressants: A mini-review of the tolerability of co-administration. Mycoses. 2009;52(5):433–9.\nPongas GN, Lewis RE, Samonis G, Kontoyiannis DP. Voriconazole-associated zygomycosis: A significant consequence of evolving antifungal prophylaxis and immunosuppression practices? Clinical Microbiology and Infection. 2009;15(SUPPL. 5):93–7.\nPongas GN, Ben-Ami R, Lewis RE, Walsh TJ, Kontoyiannis DP. Culture medium composition affects the lethality of Cunninghamella bertholletiae in a fly model of mucormycosis. Antimicrobial Agents and Chemotherapy. 2009;53(10):4569.\nLewis RE, Kontoyiannis DP. Invasive aspergillosis in glucocorticoid-treated patients. Medical Mycology. 2009;47(SUPPL. 1):S271–81.\nLewis RE. Overview of the changing epidemiology of candidemia. Current Medical Research and Opinion. 2009;25(7):1732–40.\nLeventakos K, Ben-Ami R, Lewis RE, Kontoyiannis DP. Immunomodulating effects of antifungal therapy. Current Fungal Infection Reports. 2009;3(4):243–50.\nLamaris GA, Ben-Ami R, Lewis RE, Chamilos G, Samonis G, Kontoyiannis DP. Increased virulence of zygomycetes organisms following exposure to voriconazole: a study involving fly and murine models of zygomycosis. Journal of Infectious Diseases. 2009;199(9):1399–406.\nKontoyiannis DP, Lewis RE, Marr K. The burden of bacterial and viral infections in hematopoietic stem cell transplant. Biology of Blood and Marrow Transplantation. 2009;15(1 SUPPL.):128–33.\nKofteridis DP, Lewis RE, Kontoyiannis DP. Caspofungin-non-susceptible Candida isolates in cancer patients. Journal of Antimicrobial Chemotherapy. 2009;65(2):293–5.\nGarey KW, Vo QP, Lewis RE, Saengcharoen W, LaRocco MT, Tam VH. Increased bacterial adherence and biomass in Pseudomonas aeruginosa bacteria exposed to clarithromycin. Diagnostic Microbiology and Infectious Disease. 2009;63(1):81–6.\nChamilos G, Nobile CJ, Bruno VM, Lewis RE, Mitchell AP, Kontoyiannis DP. Candida albicans Cas5, a regulator of cell wall integrity, is required for virulence in murine and toll mutant fly models. Journal of Infectious Diseases. 2009;200(1):152–7.\nBen-Ami R, Luna M, Lewis RE, Walsh TJ, Kontoyiannis DP. A clinicopathological study of pulmonary mucormycosis in cancer patients: Extensive angioinvasion but limited inflammatory response. Journal of Infection. 2009;59(2):134–8.\nBen-Ami R, Lewis RE, Raacl II, Kontoyiannis DP. Phaeohyphomycosis in a tertiary care cancer center. Clinical Infectious Diseases. 2009;48(8):1033–41.\nBen-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. Blood. 2009;114(26):5393–9.\nBen-Ami R, Lewis RE, Kontoyiannis DP. Invasive mould infections in the setting of hematopoietic cell transplantation: Current trends and new challenges. Current Opinion in Infectious Diseases. 2009;22(4):376–84.\nLewis RE, Albert ND, Kontoyiannis DP. Efficacy of single-dose liposomal amphotericin B or micafungin prophylaxis in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy. 2008;52(11):4178–80.\nLewis RE, Albert ND, Kontoyiannis DP. Comparison of the dose-dependent activity and paradoxical effect of caspofungin and micafungin in a neutropenic murine model of invasive pulmonary aspergillosis. Journal of Antimicrobial Chemotherapy. 2008;61(5):1140–4.\nLewis RE. What is the “therapeutic range” for voriconazole? Clinical Infectious Diseases. 2008;46(2):212–4.\nLamaris GA, Lewis RE, Chamilos G, May GS, Safdar A, Walsh TJ, Raad II, Kontoyiannis DP. Caspofungin-mediated β-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. Journal of Infectious Diseases. 2008;198(2):186–92.\nLamaris GA, Esmaeli B, Chamilos G, Desai A, Chemaly RF, Raad II, Safdar A, Lewis RE, Kontoyiannis DP. Fungal endophthalmitis in a tertiary care cancer center: A review of 23 cases. European Journal of Clinical Microbiology and Infectious Diseases. 2008;27(5):343–7.\nLamaris GA, Ben-Ami R, Lewis RE, Kontoyiannis DP. Does pre-exposure of Aspergillus fumigatus to voriconazole or posaconazole in vitro affect its virulence and the in vivo activity of subsequent posaconazole or voriconazole, respectively? A study in a fly model of aspergillosis. Journal of Antimicrobial Chemotherapy. 2008;62(3):539–42.\nKontoyiannis DP, Lewis RE, Alexander BD, Lortholary O, Dromer F, Gupta KL, John GT, Del Busto R, Klintmalm GB, Somani J, Lyon GM, Pursell K, Stosor V, Muňoz P, Limaye AP, Kalil AC, Pruett TL, Garcia-Diaz J, Humar A, Houston S, House AA, Wray D, Orloff S, Dowdy LA, Fisher RA, Heitman J, Albert ND, Wagener MM, Singh N. Calcineurin inhibitor agents interact synergistically with antifungal agents in vitro against Cryptococcus neoformans isolates: Correlation with outcome in solid organ transplant recipients with cryptococcosis. Antimicrobial Agents and Chemotherapy. 2008;52(2):735–8.\nGarcia-Effron G, Kontoyiannis DP, Lewis RE, Perlin DS. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrobial Agents and Chemotherapy. 2008;52(11):4181–3.\nChamilos G, Lewis RE, Lamaris GA, Albert ND, Kontoyiannis DP. Genomewide screening for genes associated with gliotoxin resistance and sensitivity in Saccharomyces cerevisiae. Antimicrobial Agents and Chemotherapy. 2008;52(4):1325–9.\nChamilos G, Lewis RE, Lamaris G, Walsh TJ, Kontoyiannis DP. Zygomycetes hyphae trigger an early, robust proinflammatory response in human polymorphonuclear neutrophils through toll-like receptor 2 induction but display relative resistance to oxidative damage. Antimicrobial Agents and Chemotherapy. 2008;52(2):722–4.\nChamilos G, Lewis RE, Kontoyiannis DP. Delaying amphotericin B-based frontline therapy significantly increases mortality among patients with hematologic malignancy who have zygomycosis. Clinical Infectious Diseases. 2008;47(4):503–9.\nChamilos G, Lewis RE, Hu J, Xiao L, Zal T, Gilliet M, Halder G, Kontoyiannis DP. Drosophila melanogaster as a model host to dissect the immunopathogenesis of zygomycosis. Proceedings of the National Academy of Sciences of the United States of America. 2008;105(27):9367–72.\nBen-Ami R, Lewis RE, Kontoyiannis DP. Immunopharmacology of modern antifungals. Clinical Infectious Diseases. 2008;47(2):226–35.\nAtkinson BJ, Lewis RE, Kontoyiannis DP. Candida lusitaniae fungemia in cancer patients: Risk factors for amphotericin B failure and outcome. Medical Mycology. 2008;46(6):541–6.\nOrciuolo E, Stanzani M, Canestraro M, Galimberti S, Carulli G, Lewis R, Petrini M, Komanduri KV. Effects of Aspergillus fumigatus gliotoxin and methylprednisolone on human neutrophils: Implications for the pathogenesis of invasive aspergillosis. Journal of Leukocyte Biology. 2007;82(4):839–48.\nMulanovich V, Lewis RE, Raad II, Kontoyiannis DP. Random plasma concentrations of voriconazole decline over time. Journal of Infection. 2007;55(5):e129–30.\nLewis RE, Liao G, Hou J, Chamilos G, Prince RA, Kontoyiannis DP. Comparative analysis of amphotericin B lipid complex and liposomal amphotericin B kinetics of lung accumulation and fungal clearance in a murine model of acute invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy. 2007;51(4):1253–8.\nLewis RE, Chamilos G, Prince RA, Kontoyiannis DP. Pretreatment with empty liposomes attenuates the immunopathology of invasive pulmonary aspergillosis in corticosteroid-immunosuppressed mice. Antimicrobial Agents and Chemotherapy. 2007;51(3):1078–81.\nLewis RE. Pharmacodynamic implications for use of antifungal agents. Current Opinion in Pharmacology. 2007;7(5):491–7.\nLamaris GA, Chamilos G, Lewis RE, Kontoyiannis DP. Virulence studies of Scedosporium and Fusarium species in Drosophila melanogaster. Journal of Infectious Diseases. 2007;196(12):1860–4.\nKontoyiannis DP, Chamilos G, Lewis RE, Giralt S, Cortes J, Raad II, Manning JT, Han X. Increased bone marrow iron stores is an independent risk factor for invasive aspergillosis in patients with high-risk hematologic malignancies and recipients of allogeneic hematopoietic stem cell transplantation. Cancer. 2007;110(6):1303–6.\nKontoyiannis DP, Chamilos G, Hassan SA, Lewis RE, Albert ND, Tarrand JJ. Increased culture recovery of zygomycetes under physiologic temperature conditions. American Journal of Clinical Pathology. 2007;127(2):208–12.\nChou LS, Lewis RE, Ippoliti C, Champlin RE, Kontoyiannis DP. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy. 2007;27(12 I):1644–50.\nChamilos G, Luna M, Lewis RE, Chemaly R, Raad II, Kontoyiannis DP. Effects of liposomal amphotericin B versus an amphotericin B lipid complex on liver histopathology in patients with hematologic malignancies and invasive fungal infections: A retrospective, nonrandomized autopsy study. Clinical Therapeutics. 2007;29(9):1980–6.\nChamilos G, Lionakis MS, Lewis RE, Kontoyiannis DP. Role of mini-host models in the study of medically important fungi. Lancet Infectious Diseases. 2007;7(1):42–55.\nChamilos G, Lewis RE, Kontoyiannis DP. Multidrug-resistant endosymbiotic bacteria account for the emergence of zygomycosis: A hypothesis. Fungal Genetics and Biology. 2007;44(2):88–92.\nChamilos G, Lewis RE, Albert N, Kontoyiannis DP. Paradoxical effect of echinocandins across Candida species in vitro: Evidence for Echinocandin-Specific and Candida species-related differences. Antimicrobial Agents and Chemotherapy. 2007;51(6):2257–9.\nWiederhold NP, Tam VH, Chi J, Prince RA, Kontoyiannis DP, Lewis RE. Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy. 2006;50(2):469–73.\nSingh N, Limaye AP, Forrest G, Safdar N, Muñoz P, Pursell K, Houston S, Rosso F, Montoya JG, Patton P, Del Busto R, Aguado JM, Fisher RA, Klintmalm GB, Miller R, Wagener MM, Lewis RE, Kontoyiannis DP, Husain S. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: A prospective, multicenter, observational study. Transplantation. 2006;81(3):320–6.\nLionakis MS, Chamilos G, Lewis RE, Wiederhold NP, Raad II, Samonis G, Kontoyiannis DP. Pentamidine is active in a neutropenic murine model of acute invasive pulmonary fusariosis. Antimicrobial Agents and Chemotherapy. 2006;50(1):294–7.\nLewis RE, Wiederhold NP, Prince RA, Kontoyiannis DP. In vitro pharmacodynamics of rapid versus continuous infusion of amphotericin B deoxycholate against Candida species in the presence of human serum albumin. Journal of Antimicrobial Chemotherapy. 2006;57(2):288–93.\nLewis RE. Managing drug interactions in the patient with aspergillosis. Medical Mycology. 2006;44(SUPPL. 1):349–56.\nLewis RE. Decision making in antifungal monotherapy versus combination therapy. Pharmacotherapy. 2006;26(6 II):61S-67S.\nLewis R. Judgments of value, judgments of fact: The ethical dimension of biohistorical research. Public Historian. 2006;28(1):93–9.\nLamaris GA, Chamilos G, Lewis RE, Safdar A, Raad II, Kontoyiannis DP. Scedosporium infection in a tertiary care cancer center: A review of 25 cases from 1989-2006. Clinical Infectious Diseases. 2006;43(12):1580–4.\nKontoyiannis DP, Lewis RE. Invasive zygomycosis: Update on pathogenesis, clinical manifestations, and management. Infectious Disease Clinics of North America. 2006;20(3):581–607.\nGarey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, Kontoyiannis DP. Evaluation of antifungals in the surgical intensive care unit: A multi-institutional study. Mycoses. 2006;49(3):226–31.\nDennis CG, Greco WR, Brun Y, Youn R, Slocum HK, Bernacki RJ, Lewis R, Wiederhold N, Holland SM, Petraitiene R, Walsh TJ, Segal BH. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47 phox-/- mouse model of chronic granulomatous disease. Antimicrobial Agents and Chemotherapy. 2006;50(2):422–7.\nChamilos G, Luna M, Lewis RE, Bodey GP, Chemaly R, Tarrand JJ, Safdar A, Raad II, Kontoyiannis DP. Invasive fungal infections in patients with hematologic malignancies in a tertiary care cancer center: An autopsy study over a 15-year period (1989-2003). Haematologica. 2006;91(7):986–9.\nChamilos G, Lionakis MS, Lewis RE. Erratum: Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species (Journal of Infectious Diseases (2006) 193 (1014-1022)). Journal of Infectious Diseases. 2006;194(9):1342.\nChamilos G, Lionakis MS, Lewis RE, Lopez-Ribot JL, Saville SP, Albert ND, Halder G, Kontoyiannis DP. Drosophila melanogaster as a facile model for large-scale studies of virulence mechanisms and antifungal drug efficacy in Candida species. Journal of Infectious Diseases. 2006;193(7):1014–22.\nChamilos G, Lewis RE, Kontoyiannis DP. Lovastatin has significant activity against zygomycetes and interacts synergistically with voriconazole. Antimicrobial Agents and Chemotherapy. 2006;50(1):96–103.\nChamilos G, Lewis RE, Kontoyiannis DP. Inhibition of Candida parapsilosis mitochondrial respiratory pathways enhances susceptibility to caspofungin. Antimicrobial Agents and Chemotherapy. 2006;50(2):744–7.\nAshley ESD, Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clinical Infectious Diseases. 2006;43(SUPPL. 1):S28–39.\nWiederhold NP, Kontoyiannis DP, Prince RA, Lewis RE. Attenuation of the activity of caspofungin at high concentrations against Candida albicans: Possible role of cell wall integrity and calcineurin pathways. Antimicrobial Agents and Chemotherapy. 2005;49(12):5146–8.\nWiederhold NP, Coyle EA, Raad II, Prince RA, Lewis RE. Antibacterial activity of linezolid and vancomycin in an vitro pharmacodynamic model of Gram-positive catheter-related bacteraemia. Journal of Antimicrobial Chemotherapy. 2005;55(5):792–5.\nTam VH, Schilling AN, Vo G, Kabbara S, Kwa AL, Wiederhold NP, Lewis RE. Pharmacodynamics of polymyxin B against Pseudomonas aeruginosa. Antimicrobial Agents and Chemotherapy. 2005;49(9):3624–30.\nStanzani M, Orciuolo E, Lewis R, Kontoyiannis DP, Martins SLR, St. John LS, Komanduri KV. Aspergillus fumigatus suppresses the human cellular immune response via gliotoxin-mediated apoptosis of monocytes. Blood. 2005;105(6):2258–65.\nRaad II, Hanna HA, Boktour M, Chaiban G, Hachem RY, Dvorak T, Lewis R, Murray BE. Vancomycin-resistant Enterococcus faecium: Catheter colonization, esp gene, and decreased susceptibility to antibiotics in biofilm. Antimicrobial Agents and Chemotherapy. 2005;49(12):5046–50.\nLionakis MS, Lewis RE, Torres HA, Albert ND, Raad II, Kontoyiannis DP. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli. Diagnostic Microbiology and Infectious Disease. 2005;52(1):15–20.\nLionakis MS, Lewis RE, May GS, Wiederhold NP, Albert ND, Halder G, Kontoyiannis DP. Toll-deficient Drosophila flies as a fast, high-throughput model for the study of antifungal drug efficacy against invasive aspergillosis and Aspergillus virulence. Journal of Infectious Diseases. 2005;191(7):1188–95.\nLionakis MS, Lewis RE, Chamilos G, Kontoyiannis DP. Aspergillus susceptibility testing in patients with cancer and invasive aspergillosis: Difficulties in establishing correlation between in vitro susceptibility data and the outcome of initial amphotericin B therapy. Pharmacotherapy. 2005;25(9):1174–80.\nLionakis MS, Lahdenranta J, Sun J, Liu W, Lewis RE, Albert ND, Pasqualini R, Arap W, Kontoyiannis DP. Development of a ligand-directed approach to study the pathogenesis of invasive aspergillosis. Infection and Immunity. 2005;73(11):7747–58.\nLewis RE, Wiederhold NP, Lionakis MS, Prince RA, Kontoyiannis DP. Frequency and species distribution of gliotoxin-producing Aspergillus isolates recovered from patients at a tertiary-care cancer center. Journal of Clinical Microbiology. 2005;43(12):6120–2.\nLewis RE, Wiederhold NP, Klepser ME. In vitro pharmacodynamics of amphotericin B, itraconazole, and voriconazole against Aspergillus, Fusarium, and Scedosporium spp. Antimicrobial Agents and Chemotherapy. 2005;49(3):945–51.\nLewis RE, Wiederhold NP, Chi J, Han XY, Komanduri KV, Kontoyiannis DP, Prince RA. Detection of gliotoxin in experimental and human aspergillosis. Infection and Immunity. 2005;73(1):635–7.\nLewis RE, Wiederhold NP. Murine model of invasive aspergillosis. Methods in molecular medicine. 2005;118:129–42.\nLewis RE, Kontoyiannis DP. Micafungin in combination with voriconazole in Aspergillus species: A pharmacodynamic approach for detection of combined antifungal activity in vitro. Journal of Antimicrobial Chemotherapy. 2005;56(5):887–92.\nKontoyiannis DP, Lionakis MS, Lewis RE, Chamilos G, Healy M, Perego C, Safdar A, Kantarjian H, Champlin R, Walsh TJ, Raad II. Zygomycosis in a tertiary-care cancer center in the era of Aspergillus-active antifungal therapy: A case-control observational study of 27 recent cases. Journal of Infectious Diseases. 2005;191(8):1350–60.\nChamilos G, Marom EM, Lewis RE, Lionakis MS, Kontoyiannis DP. Predictors of pulmonary zygomycosis versus invasive pulmonary aspergillosis in patients with cancer. Clinical Infectious Diseases. 2005;41(1):60–6.\nWiederhold NP, Kontoyiannis DP, Chi J, Prince RA, Tam VH, Lewis RE. Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: Evidence of concentration-dependent activity. Journal of Infectious Diseases. 2004;190(8):1464–71.\nTam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrobial Agents and Chemotherapy. 2004;48(11):4315–21.\nLiu W, May GS, Lionakis MS, Lewis RE, Kontoyiannis DP. Extra copies of the Aspergillus fumigatus squalene epoxidase gene confer resistance to terbinafine: Genetic approach to studying gene dose-dependent resistance to antifungals in A. fumigatus. Antimicrobial Agents and Chemotherapy. 2004;48(7):2490–6.\nLewis RE, Kontoyiannis DP. Erratum: Challenges in designing animal studies to detect antagonism of polyene activity (Antimicrobial Agents and Chemotherapy (2004) 48:8 (3211-3212)). Antimicrobial Agents and Chemotherapy. 2004;48(10):4072.\nLewis RE, Kantoyiannis DP, Najvar LK, Graybill JR, Cacciapuoti AF. Challenges in designing animal studies to detect antagonism of polyene activity.Antimicrobial Agents and Chemotherapy. 2004;48(8):3211–2.\nKontoyiannis DP, Lewis RE. Toward more effective antifungal therapy: The prospects of combination therapy. British Journal of Haematology. 2004;126(2):165–75.\nKontoyiannis DP, Lewis RE. Editorial comment: Is fluconazole the only factor? Infections in Medicine. 2004;21(1):40.\nHoffman BR, DelasAlas H, Blanco K, Wiederhold N, Lewis RE, Williams L. Screening of antibacterial and antifungal activities of ten medicinal plants from Ghana. Pharmaceutical Biology. 2004;42(1):13–7.\nBarker KS, Crisp S, Wiederhold N, Lewis RE, Bareither B, Eckstein J, Barbuch R, Bard M, Rogers PD. Genome-wide expression profiling reveals genes associated with amphotericin B and fluconazole resistance in experimentally induced antifungal resistant isolates of Candida albicans. Journal of Antimicrobial Chemotherapy. 2004;54(2):376–85.\nAndrews LB, Buenger N, Bridge J, Rosenow L, Stoney D, Gaensslen RE, Karamanski T, Lewis R, Paradise J, Inlander A, Gonen D. Constructing ethical guidelines for biohistory. Science. 2004;304(5668):215–6.\nWiederhold NP, Lewis RE, Kontoyiannis DP. Invasive aspergillosis in patients with hematologic malignancies. Pharmacotherapy. 2003;23(12 I):1592–610.\nWiederhold NP, Lewis RE. The echinocandin antifungals: An overview of the pharmacology, spectrum and clinical efficacy. Expert Opinion on Investigational Drugs. 2003;12(8):1313–33.\nTorres HA, Rivero GA, Lewis RE, Hachem R, Raad II, Kontoyiannis DP. Aspergillosis caused by non-fumigatus Aspergillus species: Risk factors and in vitro susceptibility compared with Aspergillus fumigatus. Diagnostic Microbiology and Infectious Disease. 2003;46(1):25–8.\nRogers PD, Kramer RE, Crews JK, Lewis RE. The activity of amphotericin B against Candida albicans is not directly associated with extracellular calcium concentration. Journal of Antimicrobial Chemotherapy. 2003;51(2):305–12.\nLiu W, Lionakis MS, Lewis RE, Wiederhold N, May GS, Kontoyiannis DP. Attenuation of itraconazole fungicidal activity following preexposure of aspergillus fumigatus to fluconazole. Antimicrobial Agents and Chemotherapy. 2003;47(11):3592–7.\nLionakis MS, Lewis RE, Samonis G, Kontoyiannis DP. Pentamidine is active in vitro against Fusarium species. Antimicrobial Agents and Chemotherapy. 2003;47(10):3252–9.\nLewis RE, Wiederhold NP. The solubility ceiling: A rationale for continuous infusion amphotericin B therapy? [9]. Clinical Infectious Diseases. 2003;37(6):871–2.\nKontoyiannis DP, Lewis RE, Osherov N, Albert ND, May GS. Combination of caspofungin with inhibitors of the calcineurin pathway attenuates growth in vitro in Aspergillus species. Journal of Antimicrobial Chemotherapy. 2003;51(2):313–6.\nKontoyiannis DP, Lewis RE, Lionakis MS, Albert ND, May GS, Raad II. Sequential exposure of Aspergillus fumigatus to itraconazole and caspofungin: Evidence of enhanced in vitro activity. Diagnostic Microbiology and Infectious Disease. 2003;47(2):415–9.\nKontoyiannis DP, Lewis RE. Combination chemotherapy for invasive fungal infections: What laboratory and clinical studies tell us so far. Drug Resistance Updates. 2003;6(5):257–69.\nKontoyiannis DP, Hachem R, Lewis RE, Rivero GA, Torres HA, Thornby J, Champlin R, Kantarjian H, Bodey GP, Raad II. Efficacy and toxicity of caspofungin in combination with liposomal amphotericin B as primary or salvage treatment of invasive aspergillosis in patients with hematologic malignancies. Cancer. 2003;98(2):292–9.\nAntoniadou A, Torres HA, Lewis RE, Thornby J, Bodey GP, Tarrand JJ, Han X-Y, Rolston KVI, Safdar A, Raad II, Kontoyiannis DP. Candidemia in a Tertiary Care Cancer Center: In vitro susceptibility and its association with outcome of initial antifungal therapy. Medicine. 2003;82(5):309–21.\nRoling EE, Klepser ME, Wasson A, Lewis RE, Ernst EJ, Pfaller MA. Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY 303366) alone and in combination against Candida spp. and Crytococcus neoformans via time-kill methods. Diagnostic Microbiology and Infectious Disease. 2002;43(1):13–7.\nLewis RE, Prince RA, Chi J, Kontoyiannis DP. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis. Antimicrobial Agents and Chemotherapy. 2002;46(10):3208–14.\nLewis RE, Lo H-J, Raad II, Kontoyiannis DP. Lack of catheter infection by the efg1/efg1 cph1/cph1 double-null mutant, a Candida albicans strain that is defective in filamentous growth. Antimicrobial Agents and Chemotherapy. 2002;46(4):1153–5.\nLewis RE, Kontoyiannis DP, Darouiche RO, Raad II, Prince RA. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. Antimicrobial Agents and Chemotherapy. 2002;46(11):3499–505.\nLewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. Journal of Antimicrobial Chemotherapy. 2002;49(2):345–51.\nLewis RE. Pharmacotherapy of Candida bloodstream infections: New treatment options, new era. Expert Opinion on Pharmacotherapy. 2002;3(8):1039–57.\nKontoyiannis DP, Reddy BT, Torres HA, Luna M, Lewis RE, Tarrand J, Bodey GP, Raad II. Pulmonary candidiasis in patients with cancer: An autopsy study. Clinical Infectious Diseases. 2002;34(3):400–3.\nKontoyiannis DP, Lewis RE, May GS, Osherov N, Rinaldi MG. Aspergillus nidulans is frequently resistant to amphotericin B. Mycoses. 2002;45(9–10):406–7.\nKontoyiannis DP, Lewis RE. Antifungal drug resistance of pathogenic fungi. Lancet. 2002;359(9312):1135–44.\nPietrucha-Dilanchian P, Lewis RE, Ahmad H, Lechin AE. Candida lusitaniae catheter-related sepsis. Annals of Pharmacotherapy. 2001;35(12):1570–4.\nLewis RE, Kontoyiannis DP. Rationale for combination antifungal therapy. Pharmacotherapy. 2001;21(8 SUPPL. 2):149S-164S.\nKontoyiannis DP, Andersson BS, Lewis RE, Raad II. Progressive disseminated aspergillosis in a bone marrow transplant recipient: response with a high-dose lipid formulation of amphotericin B. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America. 2001;32(5):E94-96.\nKlepser ME, Lewis RE, Ernst EJ, Rosemarie Petzold C, Bailey EM, Burgess DS, Carver PL, Lacy MK, Mercier R-C, Nicolau DP, Zhanel GG, Pfaller MA. Multi-center evaluation of antifungal time-kill methods. Journal of Infectious Disease Pharmacotherapy. 2001;5(2):29–41.\nKeele DJ, DeLallo VC, Lewis RE, Ernst EJ, Klepser ME. Evaluation of amphotericin B and flucytosine in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. Diagnostic Microbiology and Infectious Disease. 2001;41(3):121–6.\nLewis RE, Klepser ME, Pfaller MA. In vitro pharmacodynamic characteristics of flucytosine determined by time-kill methods. Diagnostic Microbiology and Infectious Disease. 2000;36(2):101–5.\nLewis RE, Klepser ME, Ernst EJ, Snabes MA, Jones RN. Comparison of oral immediate-release (IR) and extended-release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. Diagnostic Microbiology and Infectious Disease. 2000;37(1):51–5.\nKontoyiannis DP, Lewis RE, Sagar N, May G, Prince RA, Rolston KVI. Itraconazole-amphotericin B antagonism in Aspergillus fumigatus: An E-test-based strategy. Antimicrobial Agents and Chemotherapy. 2000;44(10):2915–8.\nKlepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of voriconazole pharmacodynamics using time-kill methodology. Antimicrobial Agents and Chemotherapy. 2000;44(7):1917–20.\nLewis RE, Klepser ME, Pfaller MA. Combination systemic antifungal therapy for cryptococcosis, candidiasis, and aspergillosis. Journal of Infectious Disease Pharmacotherapy. 1999;3(4):61–83.\nLewis RE, Klepser ME, Ernst EJ, Lund BC, Biedenbach DJ, Jones RN. Evaluation of low-dose, extended-interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. Antimicrobial Agents and Chemotherapy. 1999;43(8):2005–9.\nLewis RE, Klepser ME. The changing face of nosocomial candidemia: Epidemiology, resistance, and drug therapy. American Journal of Health-System Pharmacy. 1999;56(6):525–36.\nLewis RE, Lund BC, Klepser ME, Ernst EJ, Pfaller MA. Assessment of antifungal activities of fluconazole and amphotericin b administered alone and in combination against Candida albicans by using a dynamic in vitro mycotic infection model. Antimicrobial Agents and Chemotherapy. 1998;42(6):1382–6.\nLewis RE, Klepser ME, Pfaller MA. Update on clinical antifungal susceptibility testing for Candida species. Pharmacotherapy. 1998;18(3):509–15.\nLewis RE, Klepser ME. Update on clindamycin: New pharmacokinetic and pharmacodynamic data. Infections in Medicine. 1998;15(10):726–31.\nKlepser ME, Lewis RE, Pfaller MA. Therapy of Candida infections: Susceptibility testing, resistance, and therapeutic options. Annals of Pharmacotherapy. 1998;32(12):1353–61.\nKlepser ME, Ernst EJ, Lewis RE, Ernst ME, Pfaller MA. Influence of test conditions on antifungal time-kill curve results: Proposal for standardized methods. Antimicrobial Agents and Chemotherapy. 1998;42(5):1207–12."
  },
  {
    "objectID": "cv.html#bookchapters",
    "href": "cv.html#bookchapters",
    "title": "Russell Edward Lewis",
    "section": "Bookchapters",
    "text": "Bookchapters\n\nShelbourn S, Lewis RE, Kontoyiannis DP. Clinical management of infections in neutropenic patients. Hematology: Basic Principles and Practice. 8th edition. Hoffman, Benz and Shattil ed. 2021.\nKontoyiannis DP and Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. In: Principles and Practice of Infectious Diseases. Mandell, Bennet and Dolin eds. 10th edition. 2021.\nShelbourn S, Lewis RE, Kontoyiannis DP. Clinical management of infections in neutropenic patients. Hematology: Basic Principles and Practice. 7th edition. Hoffman, Benz and Shattil ed. 2017.\nKontoyiannis DP and Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. In: Principles and Practice of Infectious Diseases. Mandell, Bennet and Dolin eds. 9th edition. 2019.\nLewis RE. Pharmacokinetics of azole antifungals, Chapter 7. In: Winter’s Basic Clinical Pharmacokinetics 6th edition. Wolters Kluwer, 2018.\nLewis RE and Kontoyiannis DP. Butenafine. In: Use of antibiotics. Kucer 7 th Ed. American Society for Microbiology Press, 2017.\nLewis RE, Beyda N, Kontoyiannis DP. Caspofungin In: Use of antibiotics. Kucer 7th Ed. American Society for Microbiology Press, 2017.\nShelbourn S, Lewis RE, Kontoyiannis DP. Clinical management of infections in neutropenic patients. Hematology: Basic Principles and Practice. 6th edition. Hoffman, Benz and Shattil ed. 2017.\nCleary JD, Lewis RE. Fungal infections. Koda-Kimble & Young’s Applied Therapeutics, 11th Edition 2015.\nLewis RE., Rogers PD. Invasive Fungal Infections. Pharmacotherapy Essentials Casebook 4th Ed. MacGraw- Hill. Revised Chapter 2017.\nLewis RE. Update on Invasive fungal infections. Pharmacotherapy Self-Assessment Program-15 (PSAP-15). American College of Clinical Pharmacy.\nViale P, Lewis RE. Voriconazole treatment in invasive candidiasis. Voriconazole: Pharmacokinetics, Role in Therapeutic Drug Monitoring and Clinical Outcomes 2015. p. 41-52.\nKontoyiannis DP & Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. In: Principles and Practice of Infectious Diseases. Mandell, Bennet and Dolin eds. 8th edition. 2014.\nLewis RE. Invasive Fungal Infections. Pharmacotherapy Essentials Casebook 3rd Ed. McGraw-Hill. Revised Chapter. 2013\nLewis RE. Management of Mucormycosis. Clinical Decision Support in Medicine 2014.\nLewis RE. Invasive Fungal Infections. Pharmacotherapy Essentials 3rd Ed. McGraw-Hill. Revised Chapter 2011.\nShelbourn S, Lewis RE, Kontoyiannis DP. Management of fever in neutropenic patients. Hematology: Basic Principles and Practice. 5th edition. Hoffman, Benz and Shattil ed. 2014.\nLewis RE & Kontoyiannis DP. The clinical significance of antifungal resistance in Candida species. Candida and Candidiasis. American Society for Microbiology Press 2011.\nLewis RE and Kontoyiannis DP. Butenafine. In: Use of antibiotics. Kucer 6th Ed. American Society for Microbiology Press, 2010.\nLewis RE and Kontoyiannis DP. Glucan synthesis inhibitors. In: Use of antibiotics. Kucer 6th Ed. American Society for Microbiology Press, 2010.\nLewis RE and DS Perlin. Antifungal drug resistance. In: Management of Infections in Cancer Patients. Humana Press, 2011.\nLewis RE, Rogers PD. Invasive Fungal Infections. Pharmacotherapy Essentials 2nd Ed. MacGraw-Hill. Revised Chapter, 2010.\nKontoyiannis DP & Lewis RE. Agents of Mucormycosis and Entomophthoramycosis. In: Principles and Practice of Infectious Diseases. Mandall, Bennet and Dolin eds. 7th edition\nLewis RE. Polyene antifungal agents. In: Aspergillosis: from Diagnosis to Prevention. In Pasqualotto AC ed. Springer Press. 2009.\nLewis RE. Antifungal Drug Interactions In: Aspergillus and Aspergillosis. ASM Press 2008.\nLewis RE, Fothergill A. Antifungal Pharmacology. In: Hospenthal and Rinaldi. Clinical Mycology. Humana Press. 2008.\nLewis RE, Rogers PD. Invasive Fungal Infections. Pharmacotherapy Essentials. MacGraw-Hill. 2007.\nLewis RE. Infections in Immunocompromised Patients. In: Helms R, Quan DJ, eds. Textbook of Therapeutics: Drug and Disease Management Eighth Edition. Lippincott, Williams and Wilkins.2007\nWiederhold NP, Lewis RE. Murine model of invasive aspergillosis. Methods in Molecular Mycology. Academic Press. 2005.\nLewis RE. Management of Primary and Secondary Invasive Mycoses. Pharmacotherapy Self-Assessment Program (PSAP). American College of Clinical Pharmacy 2005.\nLewis RE, Raad II. Treatment Approaches for Catheter-Related Infections In: Biofilm Infections: Role of Antibiotic Tolerance and Resistance Marcel Dekker, Inc.\nKlepser ME, Lewis RE. Antifungal Pharmacodynamics. In: Antimicrobial Pharmacodynamics in Theory and Practice. CH Nightingale, T Murakawa, PG Ambrose (ed.). Marcel Dekker, Inc., New York, New York. 2001.\nLewis RE, Prince RA. Pharmacokinetic and pharmacodynamic principles of antimicrobial dosing in the neutropenic host. In: Febrile Neutropenia. Rubenstein E, Rolston KVI eds. Martin Dunitz, London. 2001"
  },
  {
    "objectID": "cv.html#book-translation-editor",
    "href": "cv.html#book-translation-editor",
    "title": "Russell Edward Lewis",
    "section": "Book Translation Editor",
    "text": "Book Translation Editor\nHematology: Pathophysiology, Diagnosis and Treatment (Lingua inglese). S. Tura, M. Cavo, P. Zinzani. 1st edition."
  },
  {
    "objectID": "cv.html#conference-abstractsposters",
    "href": "cv.html#conference-abstractsposters",
    "title": "Russell Edward Lewis",
    "section": "Conference abstracts/posters",
    "text": "Conference abstracts/posters\n\nLewis RE, Miller G, Reichly R, Schaiff RS, Hall T. Drug usage evaluation of G-CSF and GM-CSF at a tertiary care medical center. 1996. ASHP Midyear Clinical Meeting. New Orleans, LA December 1996.\nKlepser ME, Ernst EJ, Ernst ME, Lewis RE, Pfaller MA. Antifungal time-kill curves, influence of test conditions on results. 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1997. Toronto, Ontario, Canada\nKlepser ME, Ernst EJ, Biedenbach D, Lewis RE, Lund BC, Jones RN. Evaluation of low-dose, extended interval clindamycin regimens against Staphylococcus aureus and Streptococcus pneumoniae using a dynamic in vitro model of infection. American College of Clinical Pharmacy 1997 Annual Meeting. Phoenix, AZ.\nLund BC, Klepser ME, Ernst EJ, Lewis RE, Pfaller MA. Antifungal activity of fluconazole on _Candida albicans_in an in vitro dynamic model. American College of Clinical Pharmacy 1997 Annual Meeting. Phoenix, AZ.\nLewis RE, Klepser ME, Ernst EJ, Yeramian PD, Jones RN. Time-kill analysis of metronidazole activity against Bacteroides spp. and Clostridium difficile. American Society for Microbiology. 98th General Meeting, 1998. Atlanta, GA.\nLewis RE, Klepser ME, Pfaller MA. Evaluation of antifungal activity and the duration of the post-antifungal effect of 5-fluorocytosine monotherapy against pathogenic yeast. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. San Diego, CA.\nLewis RE, Klepser ME, Ernst EJ, Yeramian PD, Jones RN. Comparison of oral immediate-release (IR) and extended release (ER) metronidazole bactericidal activity against Bacteroides spp. using an in vitro model of infection. 38th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1998. San Diego, CA.\nDe Lallo VC, Lewis RE, Petzold RC, Pfaller MA, Klepser ME. Evaluation of amphotericin B (AmB) and flucytosine (5-FC) alone, and in combination against Candida albicans and Cryptococcus neoformans using time-kill methodology. American College of Clinical Pharmacy. 1998 Annual Meeting. Cincinnati, OH.\nKlepser ME, Malone D, Lewis RE, Ernst EJ, Pfaller MA. Evaluation of Voriconazole Pharmacodynamics Using Time-kill Methodology. Conference on Antimicrobial Agents and Chemotherapy, 1999. San Diego, CA.\nLewis RE, Klepser ME, Piscitelli SC, Groll A, De Lallo VC, Quintiliani R, Ernst EJ, Walsh T J, Pfaller MA. In vivo tissue activity of high-dose liposomal amphotericin B (AmBisome) in a neutropenic murine candidal thigh infection model. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999. San Diego, CA.\nLewis RE, Diekema DJ, Messer SA, Pfaller MA, Klepser ME. Comparison of Etest, checkerboard dilution, and time-Kill testing for the detection of synergy or antagonism among Candida spp. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999. San Diego, CA.\nKlepser ME, Lewis RE, Ernst EJ, Pfaller MA, Society of Infectious Disease Pharmacists. Multicenter evaluation of standardized methods for conducting antifungal time-kill studies. 39th Interscience Conference on Antimicrobial Agents and Chemotherapy, 1999. San Diego, CA.\nLewis RE, Turley JC. Susceptibility of community-acquired respiratory tract pathogens collected in Texas during 1998-1999: Analysis of Texas Data from the Cast Study. 38th Infectious Disease Society of America. 2000 New Orleans, LA\nRogers DP, Lewis RE, Chapman S. Antifungal activity of amphotericin B is not calcium dependent. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2000. Toronto, ONT\nLewis RE, Prince RA, Kontoyiannis DP. Pretreatment with Itraconazole Attenuates the Efficacy of Increasing Amphotericin B Dosages in a Murine Model of Invasive Pulmonary Aspergillosis. Platform Presentation-Animal Models of Infection Session. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001. Chicago, IL.\nLewis, RE, Kontoyiannis DP, Dariouche RH, Raad II, and Prince RA. Antifungal activity of amphotericin B, fluconazole, and voriconazole in an in vitro model of Candida catheter-related bloodstream infection. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001. Chicago, IL.\nLewis RE, Lo HJ, Raad II, and Kontoyiannis, DP. Lack of catheter colonization by the _cph1/cph1 efg1/efg1_double null mutant, a C. albicans strain that is defective in filamentous growth. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001. Chicago, IL.\nKontoyiannis DP, Reddy BT, Bodey GP, Luna M, Lewis RE, Tarrand J, Raad II. Pulmonary Candidiasis in Cancer Patients: An autopsy study. Platform presentation. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001. Chicago, IL\nKontoyiannis DP, Osherov N, Lewis, RE, Albert ND, May G. L-685, 818, an non-immunosuppressive calcineurin inhibitor enhances the activity of caspofungin (CAS) against Aspergillus fumigatus. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, 2001. Chicago, IL.\nLewis RE, Neuhauser MN, Tarrand J, Kontoyiannis, DP. Species Distribution and Antifungal Susceptibility of Candida Isolates from an Oncology-Specialty Hospital. American College of Clinical Pharmacy. 2001. Annual Meeting. Tampa, FL.\nCoyle E, RE Lewis, RA Prince. Activity of TMP/SMX against Stenotrophomonas maltophilia in a in vitro pharmacodynamics infection model. Infectious Diseases Society of America, 2001, San Francisco, CA.\nLewis RE, H.A. Torres, G.S. May, I.I. Raad, J. Thornby, K.V.I. Rolston, D. Upadhyaya, G. P. Bodey, D. P. Kontoyiannis. In vitro susceptibility and tolerance of Aspergillus species in a tertiary care cancer center: Correlation with invasive aspergillosis (IA) and its outcome. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA.\nLiu W, RE Lewis, GS May, D. P. Kontoyiannis. Preexposure of A. fumigatus to fluconazole induces tolerance to itraconazole in vitro. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002,San Diego, CA.\nDP Kontoyiannis, GS May, RE Lewis, ND Albert, RA Prade. Deletion of the _hog_A gene, an osmotic stress regulator, results in hypersensitivity to caspofungin in the model mould A. nidulans. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA.\nDP Kontoyiannis, R. Hachem, RE Lewis, G. Rivero, H. Kantarjian, II Raad. Efficacy and toxicity of caspofungin/liposomal amphotericin B combination (platform presentation). 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA.\nDP Kontoyiannis, RE Lewis, GS May, ND Albert, II Raad. Sequential exposure of A. fumigatus to itraconazole and caspofungin:Evidence of enhanced in vitro activity of this combination. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA.\nAntoniadou A, Torres HA, RE Lewis, II Raad, J Thornby, J Tarrand, KVI Rolston, X Han, GP Bodey, DP Kontoyiannis. Bloodstream candidiasis in cancer patients. 42nd Interscience Conf. on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA.\nCoyle E, RE Lewis, J Chi, KVI Rolston, RA Prince. Varying Doses of Levofloxacin and the Corresponding Relationship of Antimicrobial Activity and Resistance Selection against Pseudomonas aeruginosa. (Platform presentation) 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2002, San Diego, CA.\nHealy M, Reece K., Lewis RE, Kontoyiannis DP. Molecular Fingerprinting of Candida and Aspergillus species by automated rep-PCR. American Society for Microbiology 103rd General Meeting, 2003, Washington, D.C.\nRE Lewis, J. Chi, N. P. Wiederhold, D. P. Kontoyiannis, X. Han, R. A. Prince. Detection of gliotoxin, an immunologically-active metabolite secreted by Aspergillus fumigatus, in animals and humans with invasive aspergillosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nNP Wiederhold, Chi J, Kontoyiannis DP, Prince RA, Lewis RE. In vitro reduction of the Aspergillus fumigatus metabolite gliotoxin by amphotericin B, caspofungin, and voriconazole. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nNP Wiederhold, DP Kontoyiannis, J Chi, RA Prince, VH Tam, RE Lewis. In vivo pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL. Platform presentation.\nNP Wiederhold, DP Kontoyiannis, RE Lewis. In vitro pharmacodynamics of rapid vs continuous infusion amphotericin B deoxycholate in the presence of human serum albumin. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nHend HA, Chatzinikolaou, Alakech B, Hachem R, Lewis RE, Kontoyiannis DP, Tarrand JT, Raad IR. Differential positive quantitative blood cultures and the diagnosis of catheter related bloodstream infections. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nMS Lionakis, RE Lewis, HA Torres, KVI Rolston, II Raad, DP Kontoyiannis. In vitro susceptibility of Aspergillus clinical isolates to AMB, ITZ and VRC by E-test and the effect of prior antifungal exposure. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nRE Lewis, NP Wiederhold, ME Klepser. In vitro pharmacodynamics of amphotericin B, itraconazole and voriuconazole against Aspergillus, Fusarium and Scedosporium spp. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nMS Lionakis, Lahdenranta J, Liu W, RE Lewis, R Pasqualini, W. Arap, DP Kontoyiannis. Biopanning as an approach to study the pathogenesis of invasive aspergillosis. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL\nMS Lionakis, G. Halder, RE Lewis, GS May, ND Albert, DP Kontoyiannis . A non-vertebrate in vivo model to study invasive aspergillosis and its treatment with oral antifungals: early experience with Drospohila. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL. Platform presentation.\nMS Lionakis, RE Lewis, DP Kontoyiannis. Pentamidine is active in vitro against Fusarium species. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nMS Lionakis, RE Lewis, HA Torres, KVI Rolston, II Raad, DP Kontoyiannis. Comparison of the in vitro activities of modern antifungals against Aspergillus isolates from cancer patients. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nKW Garey, MM Neuhauser, DT Bearden, JP Cannon, RE Lewis, LO Gentry, DP Kontoyiannis Evaluation of antifungal usage in SICU patients: A multi-institutional study. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL. Platform presentation.\nWiederhold NP, Lewis RE, Raad, II, Coyle EA, Prince RA. Comparaison of linezolid vs. vancomycin in a simulated model of catheter-related bloodstream infections. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nVH Tam, An Shilling, RE Lewis, DA Melnick, and AN Boucher. A novel approach for studying the combined pharmacodynamics of antibacterial agents. 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2003, Chicago, IL.\nSegal, B. Bernacki, W. Slocum H., Pera, P., D. Carly. Lewis R. E. Combination antifungal therapy with micafungin (Mica) and amphotericin B desoxycholate (Amb-d) prolongs survival in the p47phox-deficient mouse model of chronic granulomatous disease (CGD) with experimental pulmonary aspergillosis. 12th Annual Focus on Fungal Infection, New Orleans, LA.\nLewis RE, NP Wiederhold, MS Lionakis, J Chi, , RA Prince, DP Kontoyiannis. Frequency and Distribution of Gliotoxin (GT)-Producing Aspergillus Isolates Recovered from Patients at a Tertiary Care Cancer Center. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C.\nM. S. Lionakis, G. Halder, R. E. Lewis, N. P. Wiederhold, D. P. Kontoyiannis. Efficacy of Voriconazole in Experimental Aspergillosis in Drosophila. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C. Platform presentation.\nM. S. Lionakis, G. Halder, R E Lewis, N. P. Wiederhold, G. S. May, D. P. Kontoyiannis. Experimental Aspergillosis in Drosophila: Influence of Mode of Infection on Aspergillus Virulence. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C.\nWiederhold NP, Kontoyiannis DP, Lewis RE. Eagle-like effect of caspofungin (CAS) against Candida and Aspergillus spp.; Association with homeostatic mechanisms of cell-wall integrity. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C. Platform Presentation.\nWiederhold NP, Kontoyiannis DP, Lewis RE. Relationship between interferon gamma/ Interleukin-10 and mycological efficacy of amphotericin B in invasive pulmonary aspergilloisis. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C.\nDP. Kontoyiannis, M. S. Lionakis , R. E. Lewis, M. Healy , G. Chamilos, G. P. Bodey, C. Perego , Safdar A, Kantarjian H, Champlin R , T. J. Walsh , I. I. Raad. Zygomycosis in the era of Aspergillus-Active Antifungal Therapy in a Tertiary Care Cancer Center: A Case Control Observational Study of 27 Recent Cases. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C. Platform Presentation.\nG. Chamilos, R.E. Lewis, D.P. Kontoyiannis. The Unique Alternative Mitochondria Susceptibility to Caspofungin (CAS). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 842.\nG. Chamilos, R. E. Lewis, M. S. Lionakis, G. Halder, D.P. Kontoyiannis. Experimental zygomycosis in Drosophila melanogaster. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1198.\nG. Chamilos, M. Luna, R. E. Lewis, A. Safdar, G. P. Bodey, I. I. Raad, D. P. Kontoyiannis. Invasive Fungal Infections An Autopsy Study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 996. Platform presentation.\nG. Chamilos, R. E. Lewis, D. P. Kontoyiannis. Lovastatin has Significant Activity against Zygomycetes In vitro and In vivo and shows In vitro Synergy with Voriconazole. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 768.\nR.E. Lewis, D. P. Kontoyiannis. Micafungin (MICA) In Combination With Voriconazole (VRC) In Aspergillus Species: A Pharmacodynamic Approach For Detection Of Synergy In Vitro. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1083.\nTam VH, A.N. Schilling, A.L. Kwa, N.P. Wiederhold, R.E. Lewis. Pharmacodynamics (PD) of Polymyxin B (PB) against Multi-drug Resistant (MDR) Pseudomonas aeruginosa (PA). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, 2004, Washington, D.C.\nR.E. Lewis, Singh N, Limaye A, Husain S, Safdar N, Munoz P, Pursell K, Kontoyiannis D. Detection Of Synergy By XTT-Enhanced Checkerboard Dilution Testing Of Aspergillus: Correlation With Outcome In Patients With Invasive Aspergillosis Treated With Combination Voriconazole (VRC) and Caspofungin (CAS) Therapy. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1053.\nG. Chamilos, R.E. Lewis, R.A. Prince, and D.P. Kontoyiannis. Zygomycetes Hyphae Are Less Susceptible To Killing By Polymorphonuclear Neutrophils (PMNs) Than Aspergillus Hyphae_,_ Through Toll-like Receptor (TLR) Independent Mechanisms. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1232.\nG. Chamilos, R.E. Lewis, D.P. Kontoyiannis. The Unique Alternative Mitochondria Susceptibility to Caspofungin (CAS). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 842.\nG. Chamilos, R. E. Lewis, M. S. Lionakis, G. Halder, D.P. Kontoyiannis. Experimental zygomycosis in Drosophila melanogaster. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1198.\nG. Chamilos, M. Luna, R. E. Lewis, A. Safdar, G. P. Bodey, I. I. Raad, D. P. Kontoyiannis. Invasive Fungal Infections An Autopsy Study. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. New Orleans, LA. Abstract 996. Platform presentation.\nG. Chamilos, R. E. Lewis, D. P. Kontoyiannis. Lovastatin has Significant Activity against Zygomycetes In vitro and In vivo and shows In vitro Synergy with Voriconazole. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC . Abstract 768.\nR.E. Lewis, D. P. Kontoyiannis. Micafungin (MICA) In Combination With Voriconazole (VRC) In Aspergillus Species: A Pharmacodynamic Approach For Detection Of Synergy In Vitro. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC Abstract 1083.\nR.E. Lewis, G. Chamilos, K.V. Komanduri, R. A, Prince, D.P. Kontoyiannis. Liposomal Amphotericin B (L-AMB) is Superior to Amphotericin B Deoxycholate (AMB-d) in Reducing Inflammatory Lung Injury (ILI) and Fungal Burden in Corticosteroid-Treated Mice with Invasive Pulmonary Aspergillosis (IPA). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1028.\nR.E. Lewis, G. Chamilos, D.P. Kontoyiannis, R. A. Prince. Pseudomonas aeruginosa (PSA) Attenuates Human Neutrophil killing of Aspergillus fumigatus (AF) Hyphae. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy. Washington, DC. Abstract 1082.\nD.P. Kontoyiannis, G. Chamilos, R.E. Lewis, J.A. Tarrand. Increased Culture Recovery of Zygomycetes under Physiologic Temperature Conditions. 43rd Infectious Disease Society of America, San Francisco, CA. Abstract 797.\nRE Lewis, G Chamilos, RA Prince, D Kontoyiannis Empty liposomes reduce inflammatory lung injury and boost PMN fungal clearance in a corticosteroid-immunosuppressed murine model of acute invasive pulmonary aspergillosis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1686. Platform presentation.\nRE Lewis, Guanling Liao, Jinggou Hou, G Chamilos, RA Prince, DP Kontoyiannis. Comparative analysis of amphotericin B lipid complex (ABLC) and lipsomal amphotericin B (L-AMB) Kinetics of Lung Accumulation and Fungal Clearance in a Murine Model of Acute Invasive Pulmonary Aspergillosis. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1689. Platform presentation.\nChamilos G, Lewis RE, Albert ND, Kontoyiannis DP. Genome-wide screening for Genes Associated with Increased gliotoxin sensitivity in Saccharomyces cerevisiae. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1782.\nBhatti, Z, Dennis C, FEminella J, Brun Y, Almyroudis NG, Lewis RE, Hollad S, Petraitiene R, Walsh TJ, Segal B. Host defense against spergillosis in the p47_phox-_/- mouse model of chronic granulomatous disease. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1683.\nChamilos G, Lewis RE, Kontoyiannis DP. Dissecting the molecular aspects of immunopathogenisis of zygomycosis in Drosophila melanongaster. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1330.\nDP Kontoyiannis, G Chamilos, Lewis RE, Manning J,Raad I, Han X. Increased bone marrow iron stores are an independent risk factor for invasive aspergillosis in severely immunocompromised cancer patients: A case control observational study. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 0295.\nGA Lamaris, Chamiols G, Lewis RE, Raad I, Kontoyiannis DP. Scedosporiosis in a tertiary care cacner center in the past 16 years. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1428.\nChamilos G, Lewis RE, Lanaris G, Walsh TJ, Kontoyiannis DP. Rhizopus hyphae trigger an early proinflammatory response in human PMNs by selective activation of TLR 2. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 1332.\nChamilos G, Lewis RE, Raad I, Kontoyiannis DP. Epidemiology and outcome of invasive zygomycosis in a tertiary care cancer center (1989-2006): A retrospective study of 95 episodes. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 0890.\nKontoyiannis DP, Chamilos G, Lewis RE, Manning J, Raad II, Han X. Increased bone marrow iron stores are an independent risk factor for invasive aspergillosis in severely immunocompromised patients: A case control study. 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract 034.\nLewis RE. What pharmacodynamics have taught us about treating fungal pneumonia: are we giving enough? 46th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA. Abstract M-0574.\nLewis R.E. Evaluating the Activity of Antifungal Agents In Vitro and In Vivo: Beyond Broth Microdilution. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL\nChamilos G., Lewis R.E., Kontoyiannis D.P. Delaying Amphotericin B (AMB)-Based Frontline Therapy Significantly Increases Mortality in Hematologic Malignancy (HM) Patients (pts) with Zygomycosis (Z). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract M-619.\nG Chamilos, Cj Nobile, Vm Bruno, RE Lewis, AP Mithcell, DP Kontoyiannis. A Novel Candida albicans Transcriptional Regulator of Cell Wall Integrity Identified Through a Screen in Toll Deficient (Tl) Flies, Promotes Virulence in Mammals. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract B-1446.\nGA Lamaris, RE Lewis, DP Kontoyiannis. Voriconazole (VRC) is Effective against Posaconazole (POSA)- Preexposed Aspergillus fumigatus (AF) in Experimental Aspergillosis in Flies. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract B-1451.\nDP Kontoyiannis, R. Lewis 1, O. Lortholory 2, N. Singh3, And Crypto Tx Study Gp; Interactions between Immunosuppressants and Antifungals against C. neoformans (C.n) and their Correlation with Outcomes in Solid Organ Transplant (SOT) Patients (pts) with Cryptococcosis. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract M-1850.\nRE Lewis, ND Albert, DP Kontoyiannis. Comparison of the Dose-Dependent Activity and Paradoxical Effect of Caspofungin (CAS) and Micafungin (MICA) in a Neutropenic Murine Model of Invasive Pulmonary Aspergillosis (IPA). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract M-1824.\nLamaris G, Lewis RE, Kontoyiannis DP. Voriconazole (VRC) Pre-Exposed Rhizopus oryzae (Rh.o) has Increased Virulence in Experimental Zygomycosis in Flies and Mice. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract B-1449.\nLamaris G, Lewis RE, Chamilos G, Kontoyiannis DP. Caspofungin (CAS) Mediated Beta-Glucan (BG) Unmasking and Enhancement of Human Neutrophil (PMN) Activity against Aspergillus spp. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL. Abstract M-1857.\nG. Lamaris, RE Lewis, G. Chamilos, Dp Kontoyiannis. Caspofungin (CAS) Mediated Beta-Glucan Unmasking and Enhancement of Neutrophil (PMN) Activity against Non-Aspergillus Moulds. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL.\nRE Lewis, G. Chamilos, ND Albert, D Kontoyianis.;Efficacy of Single-Dose Liposomal Amphotericin B (L-AMB) or Micafungin (MICA) Prophylaxis in a Persistently Neutropenic Murine Model of Invasive Pulmonary Aspergillosis (IPA). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy. Chicago, IL.\nKofteridis D, Lewis RE, Kontoyiannis DP. Caspofungin non-susceptible Candida spp isolates in cancer patients. 19th European congress of Clinical Microbiology and Infectious diseases (ECCMID). Helsinki, Finland, 05/2009.\nPongas GN, Lewis RE, Kontoyiannis DP. Aspergillus fumigatus – Pseudomonas aeruginosa: Friends or foes? 49th Annual ICAAC meeting, San Francisco, CA, 9/2009.\nBen-Ami R, Lewis RE, Leventakos K, Latge JP, Kontoyiannis DP. The importance of catalases for Aspergillus fumigatus virulence determined in a cutaneous model system. 49th Annual ICAAC meeting, San Francisco, CA, 9/2009.\nCampo M, Lewis RE, Kontoyiannis DP. Invasive Fusariosis in Patients with Hematologic Malignancy at MD Anderson Cancer Center: The Last Decade. 47th Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA, 10/2009.\nBest L, Singh N, Ben-Ami R, Albert N, Raad II, Lewis RE, Kontoyiannis DP. In Vitro Interactions of Tacrolimus with Posaconazole or Caspofungin against Zygomycetes, Annual Meeting of the Infectious Diseases Society of America (IDSA), Philadelphia, PA, 10/2009.\nLeventakos K, Lewis RE, Kontoyiannis DP. Posaconazole (POS) Plasma Concentrations in Hematological Malignancy (HM) Patients without Mucositis or Gut GVHD. 49th Annual ICAAC meeting, San Francisco, CA, 9/2009.\nLeventakos K, Lewis RE, Kontoyiannis DP. Effect of low-dose caspofungin in a neutropenic and steroid- treated murine model of pulmonary mucromycosis. 49th Annual ICAAC meeting, San Francisco, CA, 9/2009\nWatson CC, Ben-Ami R, Lewis RE, Arias C Raad II, Kontoyiannis DP. A study of the role of panton-valentine leukocidin in mrsa virulence using wild-type and toll-deficient drosophila melanogaster. 49th Annual ICAAC meeting, San Francisco, CA, 9/2009.\nBen-Ami R, Lewis RE, Leventakos K, Kontoyiannis DP. Aspergillus fumigatus inhibits angiogenesis through the production of gliotoxin and other secondary metabolites. 49th Annual ICAAC meeting, San Francisco, CA, 9/2009.\nBen-Ami R, Garcia-Effron G, Lewis RE, Leventakos K, Perlin DS, Kontoyiannis DP. Mutations in Candida albicans FKS1 conferring echinocandin resistance are associated with attenuated virulence. 49th Annual ICAAC meeting, San Francisco, CA, 9/2009.\nWatson C, Ben-Ami R, Arias C, Raad II, Lewis RE, Kontoyiannis DP. A study of the panton-velentine leukocidin in methicillin resistant Staphylococcus aureus virulence using wild-type and toll-deficient Drosophila melanogaster. Platform presentation. 47th Infectious Diseases Society of America (IDSA) Meeting, Philadelphia, PA, 2010.\nBest L, Singh N, Ben-Ami R, Raad II, Lewis RE, Konotyiannis DP. In vitro interactions of tacrolimus with posaconazole or caspofungin against zygomycetes. 47th Infectious Diseases Society of America (IDSA) Meeting, Philadelphia, PA, 2010.\nCampo M, Lewis RE, Kontoyiannis DP. Invasive fusariosis in patients with hematologic malignancy at M.D. Anderson Cancer Center. 47th Infectious Diseases Society of America (IDSA) Meeting, Philadelphia, PA, 2010.\nLeventakos K, Lewis RE, Chamilos G, Tamboli P, Raad II, Luna M, Kontoyiannis DP. Trends in epidemiology and sites of involvement by invasive fungal infections in patients with hematologic malignacies: a 20 year autopsy study. 47th Infectious Diseases Society of America (IDSA) Meeting, Philadelphia, PA 2010.\nLewis RE, G Liao, Wang W, Prince RA, Kontoyiannis DP. Comparative in vivo selection for breakthrough mucormycisis of antifungals used to treat invasive pulmonary aspergillosis. 4th Advances Against Aspergillosis Meeting, Rome, Italy 2010.\nLewis RE, ND Albert, G. Lia, Wang W, Prince RA, Kontoyiannis DP. Efficacy of dosage escalation strategies for liposomal amphotericin B in the treatment of experimental Aspergillus terreus pneumonia. 4th Advances Against Aspergillosis Meeting, Rome, Italy 2010.\nPerez C, Tam VH, Ledesma K, Abdelraouf K, Kontoyiannis DP, Lewis RE. Comparative immunoprofiling of multidrug resistant (MDR) P. aeruginosa. 50th Interscience Conference on Antimicrobial Agents Chemotherapy, Boston, MA 2011.\nSampsonas F, Lewis RE, Kontoyiannis DP. Risk stratification for early mortality in patients with hematologic cancer and invasive pulmomary mucormycosis. 50th Interscience Conference on Antimicrobial Agents Chemotherapy, Boston, MA 2011.\nLewis RE, G. Liao, Kontoyiannis DP. Use of a murine macrophage reporter cell assay to characterize the immunopharmacodynamics of caspofungin against Aspergillus fumigatus. 50th Interscience Conference on Antimicrobial Agents Chemotherapy, Boston, MA 2011.\nBen-Ami, Lewis RE, Perlin D, Kontoyiannis DP. Candida albicans FKS1 hot spot mutations associated with echinocandin resistance affect biofilm formation. 50th Interscience Conference on Antimicrobial Agents Chemotherapy, Boston, MA 2011.\nPongas GN, Lewis RE, Walsh TJ, Kontoyiannis DP. Activity of deferasirox against Mucorales: Influence of species, exogenous iron and sub-ceullular compartment. 50th Interscience Conference on Antimicrobial Agents Chemotherapy, Boston, MA. 2011.\nPongas GN, Lewis RE, Kontoyiannis DP. Invasive mould infections in pediatric cancer patients: a single institution, 10-year retrospective study. 48th Infectious Disease Society of America (IDSA) Meeting, Vancouver, BC, Canada 2011.\nBen- Ami R, Lewis RE, Kontoyiannis DP. In vitro interactions among echinocandins against Aspergillus fumigatus: Lack of concordance among methods. 48th Infectious Disease Society of America (IDSA) Meeting, Vancouver, BC, Canada 2011.\nStanzani M, Lewis RE, Fiacchini M, Ricci P, Tumietto F, Viale P, Ambretti S, Baccarani M, and Vianelli N. Development and validation of a risk-based score for invasive mold disease in patients with hematological malignancies. 17th International Meeting of the Immunocompromised Host Society. Platform presentation. Genoa, Italy. 2012.\nGirometti N, Lewis RE, Tumietto F, Ambretti S, Viale P. Bacteremia with Klebsiella penumoniae carbapenemase (KPC)-Producing Organisms: Ana analysis of attributable mortality and risk factors for recurrance. Abstract B-2333. 52nd Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, CA. 2012.\nLewis RE, Sampsonis F, Georgiadou S, Chamilos G, Kontoyiannis DP. Absolute lymphocyte count as a prognostic marker for early mortality in hematological malignancy patients with pulmonary mucormycosis.Abstract M-1994. 52nd Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, CA. 2012.\nLewis RE, Liao G, Young K, Douglas C, Kontoyiannis DP. In vitro immunopharmacodynamics of cell-wall active antifungals against Candida albicans and Aspergillus fumigatus. Abstract M-1102. 52nd Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, CA. 2012\nLewis RE, Liao G, Young K, Douglas C, Konotyiannis DP. Conditional expression of cell-wall polysaccharide- encoding genes in C. albicans and A. fumigatus reproduces immunopharmacologic effects of caspofungin and nikkomycin Z exposure. Abstract M-1105. 52nd Interscience Conference on Antimicrobial Agents Chemotherapy, San Francisco, CA. 2012.\nLewis RE, Stanzani M, Ambretti S, Viale P, Vianelli N. Prospective cross-sectional observational study of documented infections in patients with hematological malignancies. Abstract P-2124. 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany.\nBartoletti M, Girometti N, Lewis RE, Tumietto F, Cristini F, Ambretti S, Tedeschi S, Ciliberti MF, Lauria D, Finzi G, Viale P. Prospective, Cross-Sectional Observational Study of Hospitalized Patients Colonized with Carbapenemase-Resistant Klebsiella pneumoniae (CR-KP). Abstract P-968. Highlighted E-poster. 23rd European Congress of Clinical Microbiology and Infectious Diseases. Berlin, Germany.\nBartoletti M, Giannella M, Caraceni P, Domenicali M, Ambretti S, Tedeschi S, Lewis RE, Bernardi M, Viale P. Epidemiology and outcomes of bloodstream infections in patients with liver cirrhosis. 48th European Association for Study of the Liver, Amsterdam, NE 2013.\nLewis RE, Albert ND, Konotyiannis DP. Comparison of Posaconazole Pharmacodynamics in Neutropenic Murine Models of Sinopulmonary Aspergillosis and Mucormycosis. Abstract M-733. 53rd Interscience Conference on Antimicrobial Agents Chemotherapy, Denver, CO. 2013.\nLewis RE, Stanzani M, Ambretti S, Tedeschi S, Viale P, Cavo M, Vianelli N. Prospective, cross-section observational study of 1,263 infection-related hospital admissions in 787 hematological malignancy patients with fever. Abstract P-1265., 24th European Congress on Clinical Microbiology Infectious Diseases, 2104. Barcelona, Spain.\nGaibani P, Lombardo D, Bartoletti M, Tedeschi S, Giannella M, Viale P, Lewis RE, M. Landini. Serum bactericidal assay (SBA) of three antimicrobial combination therapies against KPC-producing K. pneumoniae. Abstract, EP0231. 26th European Congress of Clinical Microbiology and Infectious Diseases.\nGiannella M, Marconi L, Graziano E, Tedeschi S, Bartoletti M, Girometti N, Tumietto F, Cristini F, Ambretti S, Giabiani P, Lewis RE, Viale P. Carbapenem-resistant Klebsiella pneumoniae bacteraemia: recurrence and impact of antibiotic treatment .Abstract 0118..26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands.\nBartoletti, M, Giannella M, Lewis RE, Schramm C, Bruns T, Merli M, Cobos-Tigueros N, Paul M, Seminari E, Rodríguez-Baño J, Bouza E, Santiago, Tumbarello M, Burra P, Torrani Cerenzia, Calbo E, Barsic B, Petrosillo, Galan Ladero NM, D’Offizi G, Viale Psd. Bloodstream infection in cirrhotic patients: a prospective multicentre study (bichrome). Abstract 0312.26th European Congress of Clinical Microbiology and Infectious Diseases, Amsterdam, Netherlands.\nBartoletti, M., Tedeschi S, Pascale R, Maraolo A, Palmiero G, Luigi R, Tumietto F, Ambretti S, Cristini F, Lewis RE, Giannella M, Viale P. Does frontline use of tigecycline versus meropenem-based regimens for intra- abdominal infection reduce the risk for carbapenem resistant Klebsiella pneumoniae colonization or Clostridium difficile infection. Abstract S0893. 27th European Congress of Clinical Microbiology and Infectious Diseases, Vienna, Austria.\nGiannella M, Paolucci M, Vandi G, Roncarati G, Trapani F, Bartoletti M, Tedeschi S, Campoli C, Ambretti S, Landini M, Lewis RE, Viale P. Potential impact of T2Candida assay on the use of empiric antifungal therapy in patients at high risk for candidaemia/invasive candidiasis: a tool for antifungal stewardship programmes? Abstract P0975; 27th European Congress of Clinical Microbiology and Infectious Diseases 2017, Vienna, Austria.\nGiannella M, Campoli C, Gaibani P, Conti M, Tedeschi S, Bartoletti M, Cristini F, Tumietto F, Viale P, Lewis RE. Utility of the serum bactericidal titre assay for monitoring antimicrobial therapy of carbapenem resistant Klebsiella pneumoniae. Abstract P1209. 27th European Congress of Clinical Microbiology and Infectious Diseases, 2017. Vienna, Austria.\nPaolucci M, Roncarati G, Landini M, Lewis RE. Antifungal susceptibility testing for Candida spp.: agreement between EUCAST reference method and commercial tests. Abstract 0134. 27th European Congress of Clinical Microbiology and Infectious Diseases, 2017. Vienna, Austria.\nBartoletti M, Giannella M, Tedeschi S, Lewis RE, Viale P. Continuous infusion of beta-lactam antibiotics in patients with liver cirrhosis and bloodstream infection: results from a prospective, multicentre study. Abstract 0094. 28th European Congress of Clinical Microbiology and Infectious Diseases, 2018. Madrid, Spain.\nLewis RE, Beyda N, Albert ND, Kontoyiannis D. In vitro pharmacodynamics of isavuconazole, voriconazole, and posaconazole against agents of aspergillosis, mucormycosis, phaeohyphomycosis, fusariosis, and scedosporiosis. Abstract 0297. 28th European Congress of Clinical Microbiology and Infectious Diseases, 2018. Madrid, Spain.\nGiannella M, Pascale R, Toschi A, Ferraro G, Furii F, Bartoletti M, Tedeschi S, Graziano E, Ambretti S, Lewis RE, Viale P. Impact of treatment duration on the risk of relapse in patients with Escherichia coli bloodstream infection Abstract 01184. 28th European Congress of Clinical Microbiology and Infectious Diseases, 2019, Amsterdam, Netherlands.\nGlampedakis E, Cassaing S, Fekkar A, Dannaoui E, Bougnoux M, Bretagne S, Neofytos D, Schreiber P, Hennequin C, Morio F, Shadrivova O, Bongomin F, Fernandez Ruiz M, Bellanger A, Arikan-Akdagli S, Erard V, Aigner M, Paolucci M, Charpentier E, Bonnal C, Brun S, Gabriel F, Riat A, Zbinden R, Le Pape P, Klimko N, Lewis RE, Richardson M, İnkaya A, Coste A, Lamoth F. Invasive aspergillosis due to Aspergillus section Usti: a European multi-centre study. Abstract 01184. 28th European Congress of Clinical Microbiology and Infectious Diseases, 2019, Amsterdam, Netherlands.\nGiannella M, Bartoletti M, Campoli C, Rinaldi M, Coladonato S, Pascale R, Tedeschi S, Ambretti S, Cristini F, Siniscalchi A, Bertuzzo V, Morelli M, Cescon M, Pinna A, Lewis RE, Viale P. Carbapenem-resistant Enterobacteriaceae infection risk after liver transplantation: the impact of colonisation. Abstract 01144. 28th European Congress of Clinical Microbiology and Infectious Diseases, 2019, Amsterdam, Netherlands.\nStanzani M , Sassi C, Sartor C, Battista G, Coppola P, and Lewis RE. Early Low-Dose Computed Tomography with Pulmonary Angiography to Improve the Diagnosis of Invasive Mould Disease in Patients with Haematological Malignancies: A Pilot Clinical Study. 9th Advances in Aspergillosis and Mucormycosis Meeting, Lugano, Switzerland."
  },
  {
    "objectID": "cv.html#web-content",
    "href": "cv.html#web-content",
    "title": "Russell Edward Lewis",
    "section": "Web Content",
    "text": "Web Content\n\nEchinocandin Antifungals Monograph, Up to Date http://www.uptodate.com\nMycoses Study Group/Doctor Fungus Website. http://www.doctorfungus.org/\nDoctor Fungus Website Editor, Antifungal Pharmacology Pages, 2001-2012. http://www.doctorfungus.org (2002-2007)\nPharmacoeconomic of antifungal therapy-Primary and Secondary Costs. Dr. Fungus Website http://www.doctorfungus.org/\nPharmacokinetic optimization of itraconazole therapy.  Fungal Research Trust- Aspergillus Website (Dr. David Denning, Editor) http://www.aspergillus.man.ac.uk\nAntifungal Pharmacology Module. Fungal Research Trust-Aspergillus Website (Dr. David Denning, Editor) http://www.aspergillus.man.ac.uk"
  },
  {
    "objectID": "cv.html#editorial-boards",
    "href": "cv.html#editorial-boards",
    "title": "Russell Edward Lewis",
    "section": "Editorial Boards",
    "text": "Editorial Boards\n2022 Senior Editor, Pharmacokinetics/Pharmacodynamics Section, Journal of Antimicrobial Chemotherapy  British Socieity of Antimicrobial Chemotherapy\n2016-2021 Associate Editor, Journal of Antimicrobial Chemotherapy  British Socieity of Antimicrobial Chemotherapy\n2013-2020 Deputy Editor, Mycoses  Deutschsprachige Mykologische Gesellschaft\n2013-2015 Editor, Current Fungal Infection Reports  Springer Publishing\n2006-present Editorial board, Antimicrobial Agents Chemotherapy  American Society for Microbiology\n2006-2011 Editorial board, Pharmacotherapy  American College of Clinical Pharmacy"
  },
  {
    "objectID": "cv.html#grant-or-guideline-committees",
    "href": "cv.html#grant-or-guideline-committees",
    "title": "Russell Edward Lewis",
    "section": "Grant or guideline committees",
    "text": "Grant or guideline committees\n2022-present Medical Research Council, Infection and Immunity Section, United Kingdom\n2019-present French -German Call for Projects on Antimicrobial Resistance AMR\n2019-present European Society for Clinical Microbiology and Infectious Diseases\n2019-present European Congress on Clinical Microbiology and Infectious Diseases\n2016-present British Society for Antimicrobial Chemotherapy\n2018-present Foundation for Polish Science\n2015 European Committee on Infections in Leukemia-6 (ECIL-6): Guidelines.  Antifungal pharmacology and therapeutic drug monitoring committee chair\n2014 European Society of Clinical Microbiology and Infectious Diseases  Aspergillosis Guidelines Committee Chair: Pharmacology Section\n2011-present Mycoses Study Group Education and Research Consortium, [http://msgerc.org/]__(http://msgerc.org/)\n2011 Infectious Diseases Pharmacology Reviewer, Austrian Science Fund\n2010 NIH/NIAID RFA AI-09-026 and -029, Partnerships for Development of Therapeutics and Diagnostics for Drug-Resistant Bacteria and Eukaryotic Parasites\n2010 External Ad-Hoc Reviewer, U.S. Armed Forces IRB\n2010 Ad-Hoc Reviewer, National Aeronautics and Space Administration (NASA)\n2011-present Netherlands Organization for Scientific Research. Council for the Earth and Life Sciences Grant\n2009 University of Texas NIH SCORE Proposals\n2006 European Commission. Program for Research, Technological Development and Demonstration- Infectious Diseases., 6th Framework Programme"
  },
  {
    "objectID": "cv.html#service",
    "href": "cv.html#service",
    "title": "Russell Edward Lewis",
    "section": "Service",
    "text": "Service\nUniversity of Bologna  2015-present English Medical School Curriculum Development Committee Consiglio del CdL in Medicine and Surgery\nUniversity of Houston  2006-2011 University of Houston Research Council 2004-2006\n2006-2011 University Institution Biosafety Committee\n2004-2005 Chair, UH College of Pharmacy Research Committee\n2007-2010 UH College of Pharmacy P&T Committee\n2000-2007 UH College of Pharmacy Research Committee\n2000-2007 UH College of Pharmacy Graduate Affairs Committee\n2003 UH College of Pharmacy Education Subcommittee on Curricular Issues\n2002-2004 UH Library and Information Technology Committee 2002-2004\n2009-2011 UH College of Pharmacy AACP Accreditation Self-Study Committee 2009-2011\nNational  2008-2010 Society of Infectious Diseases Pharmacists (SIDP) Board of Directors (national elected position)\n2002-2004 Chair, ASHP Clinical Practice Network-Infectious Diseases\n2003-2009 Society of INfectious Diseases Pharmacists (SIDP) Research Committee 2003-2009; Chair (2007-2009)\n2001-2002 Chair, Internet Committee, Society of Infectious Disease Pharmacists\n2001-2002 Guidelines and Publications Committee, American Society of Clinical Pharmacy\n1998-1999 Publications Committee, Society of Infectious Diseases Pharmacists\n1998-1999 Publications Committee, Americal College of CLinical Pharmacy, Infectious Diseases"
  },
  {
    "objectID": "cv.html#awards",
    "href": "cv.html#awards",
    "title": "Russell Edward Lewis",
    "section": "Awards",
    "text": "Awards\n 1995 Facts and Comparison Excellence in Clinical Medical Communications\n1999 ACCP Best poster award finalist\n2002 Outstanding Faculty Achievement in Research Award, University of Houston\n2002 Manuscript Selected-ASM News Journal Highlights (May 2002)\n2002 Phi Lambda Sigma Honorary Faculty Lifetime Member Inductee\n2002 Society of Infectious Diseases Pharmacists Young Investigator of the Year Award\n2004 University of Houston College of Pharmacy Clinical Faculty Preceptor of the Year\n2004 Merck Award for Outstanding Achievement in Pharmacy Education\n2005 Fellow, American College of Clinical Pharmacy\n2005 University of Houston College of Pharmacy Award for Outstanding Faculty Service\n2009 University of Houston College of Pharmacy Award for Outstanding Research Achievement\n2010 University of Houston College of Pharmacy Faculty Clinical Preceptor of the Year\n2010 University of Houston Award for Excellence in Faculty Research-Associate Professor Level  (University-wide award voted by committee of faculty from across the University"
  }
]